



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Shedding of SARS-CoV-2 in feces and urine and its potential role in person-to-person transmission and the environment-based spread of COVID-19

Citation for published version:

Jones, DL, Baluja, MQ, Graham, DW, Corbishley, A, McDonald, JE, Malham, SK, Hillary, LS, Connor, TR, Gaze, WH, Moura, IB, Wilcox, MH & Farkas, K 2020, 'Shedding of SARS-CoV-2 in feces and urine and its potential role in person-to-person transmission and the environment-based spread of COVID-19', *Science of the Total Environment*. <https://doi.org/10.1016/j.scitotenv.2020.141364>

Digital Object Identifier (DOI):

[10.1016/j.scitotenv.2020.141364](https://doi.org/10.1016/j.scitotenv.2020.141364)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Science of the Total Environment

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Shedding of SARS-CoV-2 in feces and urine and its potential role in person-to-person transmission and the environment-based spread of COVID-19

David. L. Jones^{a,b} ✉, Marcos Quintela Baluja^c, David W. Graham^c, Alexander Corbishley^d, James E. McDonald^a, Shelagh K. Malham^e, Luke S. Hillary^a, Thomas R. Connor^{f,g}, William H. Gaze^h, Ines B. Mouraⁱ, Mark H. Wilcox^j, Kata Farkas^{a,e}

^a *Centre for Environmental Biotechnology, School of Natural Sciences, Bangor University, Bangor, Gwynedd, LL57 2UW, UK*

^b *UWA School of Agriculture and Environment, The University of Western Australia, Perth, WA 6009, Australia*

^c *School of Engineering, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK*

^d *The Roslin Institute and Royal (Dick) School of Veterinary Studies, Easter Bush Campus Midlothian, EH25 9RG, UK*

^e *School of Ocean Sciences, Bangor University, Menai Bridge, Anglesey, LL59 5AB, UK*

^f *Organisms and Environment Division, School of Biosciences, Cardiff University, Cardiff, CF10 3AX, UK*

^g *Public Health Wales, University Hospital of Wales, Cardiff, CF14 4XW, UK*

^h *European Centre for Environment and Human Health, University of Exeter Medical School, ESI, Penryn Campus, TR10 9FE UK*

ⁱ *Leeds Institute for Medical Research, Faculty of Medicine and Health, University of Leeds, Leeds, LS1 3EX, UK*

^j *Healthcare Associated Infections Research Group, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK*

✉e-mail d.jones@bangor.ac.uk

Abstract

The recent detection of SARS-CoV-2 RNA in feces has led to speculation that it can be transmitted via the fecal-oral/ocular route. This review aims to critically evaluate the incidence of gastrointestinal (GI) symptoms, the quantity and infectivity of SARS-CoV-2 in feces and urine, and whether these pose an infection risk in sanitary settings, sewage networks, wastewater treatment plants, and the wider environment (e.g. rivers, lakes and marine waters). A review of 48 independent studies revealed that severe GI dysfunction is only evident in a small number of COVID-19 cases, with $11 \pm 2\%$ exhibiting diarrhea and $12 \pm 3\%$ exhibiting vomiting and nausea. In addition to these cases, SARS-CoV-2 RNA can be detected in feces from some asymptomatic, mildly- and pre-symptomatic individuals. Fecal shedding of the virus peaks in the symptomatic period and can persist for several weeks, but with declining abundances in the post-symptomatic phase. SARS-CoV-2 RNA is occasionally detected in urine, but reports in fecal samples are more frequent. The abundance of the virus genetic material in both urine (ca. 10^2 - 10^5 gc/ml) and feces (ca. 10^2 - 10^7 gc/ml) is much lower than in nasopharyngeal fluids (ca. 10^5 - 10^{11} gc/ml). There is strong evidence of multiplication of SARS-CoV-2 in the gut and infectious virus has occasionally been recovered from both urine and stool samples. The level and infectious capability of SARS-CoV-2 in vomit remain unknown. In comparison to enteric viruses transmitted via the fecal-oral route (e.g. norovirus, adenovirus), the likelihood of SARS-CoV-2 being transmitted via feces or urine appears lower due to the lower relative amounts of virus present in feces/urine. The biggest risk of transmission will occur in clinical and care home settings where secondary handling of people and urine/fecal matter occurs. In addition, while SARS-CoV-2 RNA genetic material can be detected by in wastewater, this signal is greatly reduced by conventional treatment. Our analysis also suggests the likelihood of infection due to contact with sewage-contaminated water (e.g. swimming, surfing, angling) or food (e.g. salads, shellfish) is extremely low or negligible based on very low predicted abundances and limited environmental survival of SARS-CoV-2. These

conclusions are corroborated by the fact that tens of million cases of COVID-19 have occurred globally, but exposure to feces or wastewater has never been implicated as a transmission vector.

Keywords: bathing waters, coronavirus, faecal-oral route, infection risk, sanitation, waterborne illness

1. Introduction

In recent years, several viral epidemics have impacted human populations, resulting in substantial morbidity, mortality and a negative impact on the global economy [e.g. Zika virus (ZIKV), Ebola virus (EBOV), severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV)](Peckham, 2013; Watkins, 2018). Of these, respiratory viruses such as coronaviruses (CoV) have proven particularly problematic to control due to their ease of human-to-human transmission and wide range of primary and secondary animal reservoirs (Assiri et al., 2013; Damas et al., 2020). They were also recently highlighted by the World Health Organization in 2018 as priority areas for research given their potential to cause a public health emergency and the absence of efficacious drugs and/or vaccines (WHO, 2018). To date, seven human coronaviruses (HCoV) have been identified that can induce a range of respiratory symptoms with variable case fatality rates. These include the circulating seasonal HCoVs (i.e. higher winter prevalence) that are generally considered to cause mild respiratory symptoms (α CoVs; HCoV-229E and HCoV-NL63, β -CoVs; HCoV-HKU1 and HCoV-OC43), through to novel CoVs that lead to severe and potentially fatal respiratory tract infections (β -CoVs; SARS-CoV-1, MERS-CoV and SARS-CoV-2)(Gaunt et al., 2010; Guo et al., 2020a; Pfefferle et al., 2011). The novel Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, presents with a range of respiratory symptoms which, in an estimated 14-17% of cases, leads to severe or critical disease such as severe pneumonia or acute respiratory distress syndrome (ARDS)(Petrosillo

et al., 2020; Wu and McGoogan, 2020; Docherty et al., 2020). Although SARS-CoV-2 belongs to the same β -CoV genus as the CoVs responsible for the severe acute respiratory syndrome (SARS; caused by SARS-CoV) and Middle East respiratory syndrome (MERS; caused by MERS-CoV), this newly emerged virus tends to be associated with milder infections. For example, depending on the country, case fatality rates from COVID-19 have been estimated to be ca. 1-5%, significantly lower than the death rates for SARS (9.5%) and MERS (35%)(Wu and McGoogan, 2020; De Wit et al., 2016; Rajgor et al., 2020; CDC, 2020). In addition, SARS and MERS are predominantly associated with nosocomial spread, whereas SARS-CoV-2 is much more widely transmitted in the community, particularly in places with high population densities such as overcrowded housing, industrial processing plants, elderly care homes, and prisons (Abrams et al., 2020; Cloud et al., 2020; Franco-Paredes et al., 2020; Petrosillo et al., 2020; Razum et al., 2020; Waltenburg et al., 2020).

Coronaviruses are enveloped, positively charged (at neutral pH), single-stranded viruses that possess the largest genomes of all known RNA viruses (26.4 to 31.7 kb), giving them considerable plasticity to accommodate, acquire and modify genes, enabling jumps between animal hosts (Woo et al., 2010; Perlman and Netland, 2009). This is mainly evidenced by the observed spillover of SARS, MERS and now SARS-CoV-2, the emergence of new variants of SARS-CoV-2 and thus the possibility for antigenic drift (Koyama et al., 2020). The genome size of SARS-CoV-2 lies at the upper end of the coronavirus range (29.9 kB), encoding a total of 11 genes with 11 open reading frames (Yoshimoto, 2020). The direct ancestor of SARS-CoV-2 appears to have been circulating unnoticed for decades in bats and subsequently transmitted to pangolins and then humans (Boni et al., 2020). SARS-CoV-2 is 96.2% identical to the bat CoV RaTG13, and is far more distantly related to both SARS-CoV-1 (79.5% identity) and MERS-CoV (50% identity) (Guo et al., 2020a; Paraskevis et al., 2020; Rabaan et al., 2020; Andersen et al., 2020). The genetic differences between SARS-CoV-1 and SARS-CoV-2 (380 amino acid substitutions) are largely clustered in non-

structural protein genes; however, 27 mutations also are present in genes encoding the viral spike protein S responsible for receptor binding and cell entry. These differences have resulted in contrasting patterns of human infection (e.g. antigen detection) and replication compared with both SARS-CoV-1 and MERS-CoV. Consequently, the use of past studies on SARS-CoV-1 and MERS-CoV to explain the transmission and environmental behaviour of SARS-CoV-2 should be done with caution. Although SARS-CoV-2 is thought to be largely spread by the inhalation of contaminated respiratory droplets or via contact with fomites, the fecal-oral route also has been suggested in its spread due to the fact that infected persons can shed SARS-CoV-2 RNA in bodily fluids (e.g. feces and to a lesser extent urine; Peng et al., 2020a; Zhang et al., 2020). However, considerable debate exists about the relative importance of this pathway, partially because a comprehensive review does not yet exist.

Here we critically assess current and previous available evidence on (i) gastrointestinal (GI) symptoms associated with COVID-19, (ii) the behavior of SARS-CoV-2 in the GI tract, (iii) the abundance of SARS-CoV-2 in feces and urine, (iv) the evidence that SARS-CoV-2 remains infectious after release from the body, and (v) whether feces and urine in sanitary environments, sewage systems and wastewater consequently pose a risk to human health.

2. Proportion of COVID-19 cases showing gastrointestinal symptoms

Patients infected with SARS-CoV-2 typically exhibit a wide range of symptoms including fever, coughing, dyspnea, sore throat and headaches. In addition, GI symptoms including nausea, vomiting, loss of appetite, diarrhea, and abdominal pain have been reported (Lo et al., 2020; Adhikari et al., 2020). GI problems are also observed in other acute respiratory infections (e.g. influenza viruses, human rhinoviruses) and have been reported as a very common symptom of severe influenza in children (Poole et al., 2020). In some cases, this is due to co-infections with

other organisms, but is frequently due to simultaneous viral replication in multiple organs, including the GI tract (Minodier et al., 2017; Rovida et al., 2013).

Most reports on the symptoms of COVID-19 are derived from clinical cases. From these, however, the number, range and severity of symptoms associated with COVID-19 can vary largely from person to person. Overall, our analysis of the symptoms from 48 independently published studies involving thousands of individuals has shown that a small, but significant number of patients experience gastrointestinal problems. Incidence of GI complaints, vomiting and diarrhea is similar to SARS-CoV-1 and MERS-CoV (Rabaan et al., 2020; Kanwar et al., 2017). Current evidence also suggests that rates of GI symptoms from SARS-CoV-2 are comparable in both children and adults in symptomatic cases. However, it should be noted that there is a greater proportion of asymptomatic carriage and mild infections in children in comparison to adults (Dong et al., 2020; Wang et al., 2020a). Further, other studies suggest the incidence of diarrhea is greatest in severely ill patients, while abdominal pain and vomiting are not (Yang et al., 2020; Tian et al., 2020). Our analysis suggests that, on average, the number of hospitalized cases experiencing diarrhea is $11\% \pm 2\%$ while those exhibiting vomiting and nausea is $12\% \pm 3\%$ (mean \pm SEM, $n = 48$ independent studies). It is unknown from the reported data to what extent these symptoms co-occur. In a rare number of cases, diarrhea has been shown to be the only COVID-19 symptom, making these cases very difficult to diagnose (Li et al., 2020a; Taxonera et al., 2020). Although there are reports of renal organ failure from SARS-CoV-2 in severe infections (Martinez-Rojas et al., 2020), there are fewer reports of urinary dysfunction as a result of infection (Prabhu et al., 2020). It should be noted that injury to the renal system is common in COVID-19 cases, but that in most individuals these effects are subclinical (Martinez-Rojas et al., 2020). Further, the data presented in Figure 1 does not account for SARS-CoV-2 infections that are either asymptomatic or very mild, and do not require hospitalization. Asymptomatic cases may account for ca. 40-45% of SARS-CoV-2 infections, with the potential to transmit the virus for extended periods, possibly

longer than 14 days (Oran and Topol, 2020). It is therefore likely the incidence of these symptoms is greater than shown in Figure 1. This underreporting is common for gastrointestinal infections (Fletcher et al., 2013; Gleizes et al., 2006). The variability in the data may also be associated with different reporting criteria for each condition used in the different studies (Kwan et al., 2005). Further, data may also be slightly confounded due to the administration of anti-viral drugs, antibiotics and traditional and alternative medicines to patients that also induce diarrhea and vomiting (Tian et al., 2020). Consequently, diarrhea in COVID-19 patients is not always associated with SARS-CoV-2 and may explain why GI symptoms do not correlate well with the severity of diseases or worse outcomes (Aguila et al., 2020; Cao et al., 2020). While self-reporting of SARS-CoV-2 infection and symptoms has been used in some countries to capture mild cases of COVID-19, these data have large uncertainties due to ‘hypochondriacal suspicion’ and the inclusion of symptoms from other diseases also circulating in the population (Gong et al., 2020). For this reason, this type of data was considered unreliable.

As evidenced from Figure 1, abdominal pain is a common symptom of COVID-19. The extent to which this is directly due to viral infection of the GI tract or from general anxiety, however, remains unknown. A range of studies have shown that the threat of contracting COVID-19 can induce a range of somatic symptoms (e.g. sleep dysfunction, GI pain, headaches; Liu et al., 2020a; Yuan et al., 2020; Shevlin et al., 2020). Somatic symptoms of nausea, vomiting, abdominal pain and diarrhea are also known to be common in society. In some cases, the levels of these GI-related symptoms in society are consistent with reports for symptom frequency in COVID-19 cases (Haug et al., 2002a,b).

We conclude from our analysis that SARS-CoV-2 clearly causes gastrointestinal dysfunction in a small, but substantial proportion of COVID-19 cases (ca. 5-20%). However, the likelihood of prevalence could be much greater due to underreporting of mild infections. In

addition, due to the prevalence of somatic symptoms, these symptoms should not be used as direct evidence for actual GI infection.

3. Fecal shedding patterns of SARS-CoV-2

Consistent with the symptoms presented in Fig. 1, SARS-CoV-2 RNA has been routinely detected in upper and lower respiratory tract fluids, sputum, saliva, stool, blood, and urine of infected persons (Yan et al., 2020; Lu et al., 2020). The presence of the virus in feces appears to be similar in patients both with and without GI symptoms (Lin et al., 2020). Overall, however, SARS-CoV-2 is mostly detected in respiratory tract samples (typical range 70-100%), to a lesser extent in stool (typical range 30-60%), and rarely in urine (<5%)(Lo et al., 2020; Huang et al., 2020a; Kashi et al., 2020). In a few cases, even though it cannot be detected in the upper respiratory tract, the virus can be found in stools (Zhang et al., 2020b; Ling et al., 2020). However, in these cases the potential for false-negatives cannot be discounted (Piras et al., 2020). This range of symptoms has led to speculation that there are two different subtypes of COVID-19 manifestations referred to as “gut-tropism” and “lung-tropism”, depending on where the virus enters the body (i.e. inhaled or ingested) and becomes established, and thus where symptoms develop (Lo et al., 2020). There is no evidence, however, to support this or that some strains of SARS-CoV-2 preferentially target the GI tract in comparison to the respiratory tract (Iwasaki and Grubaugh, 2020).

Shedding of the virus in feces and in respiratory droplets may occur ca. 3-5 days before other classic symptoms, such as fever or diarrhea manifest (i.e. pre-symptomatic; Buscarini et al., 2020; Wang et al., 2020b; He et al., 2020a). Current evidence suggests that despite showing no symptoms, asymptomatic, pre-symptomatic or post-symptomatic people may still be shedding the virus at appreciable levels, although asymptomatic individuals may not shed it for as long or in as high amounts as in severely infected individuals that require hospitalization (Lu et al., 2020; Su et al., 2020a; Shen et al., 2020; Chau et al., 2020; Byrne et al., 2020). Critically, however, it is not

well established whether viral loads are similar between asymptomatic, and mild, moderate, or severe symptomatic cases, with conflicting reports present in the literature (Wang et al., 2020a; Lu et al., 2020; He et al., 2020a; Liu et al., 2020b; Li et al., 2010b; Schwierzeck et al., 2020; Zou et al., 2020). However, we note that if the viral loads are similar, the lack of coughing and diarrhea in asymptomatic cases should lower the risk of disease transmission.

The information available so far from COVID-19 cases suggests the temporal dynamics of viral shedding in feces follows a classic infection cycle pattern (i.e. rapid build-up phase followed by a slow decline)(Sethuraman et al., 2020; Fig. 2). This is somewhat similar to that seen for SARS-CoV-1 where the rate of viral shedding in feces is low in the first five days of illness, but rises gradually to peak at days 9-14 with very high titers, often exceeding those of nasopharyngeal aspirates (Cheng et al., 2004). However, unlike SARS-CoV-1, it is known that shedding and transmission occurs with SARS-CoV-2 prior to symptom onset (Wei et al., 2020). In the case of SARS-CoV-2, initial reports provide good evidence of the rapid accumulation of viral loads in feces (Zhang et al., 2020b) and that it can be detected in stools of fecal-positive patients for at least two weeks after the decline of symptoms (Pan et al., 2020b). Since these early reports, the amount of fecal-positive cases in cohort-studies has been shown to be up to 75% of the total (Yan et al., 2020). Critically, however, it suggests that not all COVID-19 infections result in pronounced fecal shedding, consistent with the incidence of symptoms presented in Fig. 1. In addition, diarrhea is not always associated with viral shedding (Young et al., 2020). Taking all the available evidence on the temporal dynamics of viral shedding in feces suggests that shedding may occur for ca. five days prior to symptoms developing, ca. one week prior to hospitalization, and then for two weeks after symptoms have subsided (Lo et al., 2020; Byrne et al., 2020; Hosoda et al., 2020). Another diagnostic feature of COVID-19 cases is that SARS-CoV-2 can often be found in stool samples even after throat swabs appear negative in the post-symptomatic phase (Du et al., 2020a; Zhang et al., 2020a; Gupta et al., 2020; Xu et al., 2020; Jiang et al., 2020). For example, the median (IQR)

time of detectable viral RNA was 18.5 (13-22) days for throat swabs, 22 (18-27) days for sputum, and 17 (11-32) days for stools (Fig. 2). In addition, viral loads in sputum and stool appear to decline slower than in throat swabs, with the longest shedding period recorded at 59 days (Huang et al., 2020b; Xiao et al., 2020b; Xu et al., 2020; Wu et al., 2020a). This has led to the suggestion that detection of SARS-CoV-2 in stool samples should be used alongside testing of viral presence in sputum and saliva samples (Ahamed Mim et al., 2020; Liu et al., 2020c; Ma et al., 2020; Mesoraca et al., 2020). However, in the late stages of infection it is possible that SARS-CoV-2 in feces **may not be infectious** and that RNA-based testing may result in unnecessary hospital bed-occupancy. Critically, this is supported by Hua et al. (2020) who found no transmission from fecal-positive children to family members.

4. Multiplication of SARS-CoV-2 in the gut

The evidence presented above has also led to the supposition that the fecal-oral route may be an opportunity for transmission of SARS-CoV-2 (Xu et al., 2020), as suggested previously also for SARS-CoV-1 and MERS-CoV (Yan et al., 2020). It is well established that stool samples contain an abundance of viruses in the human body and are an integral part of the transmission pathway for many pathogenic viruses (e.g. bocavirus, norovirus, rotavirus, astrovirus, sapovirus, adenovirus; Rovida et al., 2013; Drosten et al., 2013). Of the estimated 1.4 billion cases of diarrhea worldwide each year, viruses make up a considerable portion (Xie et al., 2013; Kotloff et al., 2019). Although seasonal HCoVs only make up a small proportion of these cases in comparison to viruses such as norovirus (NoV), rotavirus (RoV), rhinovirus (RhV) and adenovirus (AdV), it does imply that SARS-CoV-2 is not unusual in inducing GI problems and this symptom may represent a part of its infection cycle (Fig. 3) (Rovida et al., 2013; Drosten et al., 2013; Kheyami et al., 2010; Esper et al., 2010; Risku et al., 2010).

If sputum is swallowed, viral particles enveloped in mucus may pass down the GI tract in a semi-protected state and avoid degradation by gastric acid and bile/pancreatic juices (Hirose et al., 2017). This is likely to provide a primary route for infection of the GI tract, post-establishment of the virus in the upper respiratory tract. In addition, SARS-CoV-2 contained in sputum and saliva may also ultimately contribute to the viral load in feces, especially given the high viral load in these fluids and the large amounts (ca. 1.0-1.5 l person⁻¹) produced and swallowed per day (Rudney et al., 1995; Iorgulescu, 2009). Although SARS-CoV-2 has been detected in blood, the prevalence rates are extremely low (ca. 1% of infections exhibit viremia; Lam et al., 2020), suggesting that this is not a primary route of infection of GI tract tissues and is a secondary manifestation of COVID-19. It is also possible that SARS-CoV-2 may reach the GI tract via contaminated food, however, there are no documented cases of food-borne transmission of SARS-CoV-2 (Li et al., 2021). A rare exception to this would be the handling and consumption of products from animals which have contracted the virus. The widespread risk of this, however, is likely to be extremely low based on evidence from previous SARS-CoV-1 and MERS-CoV outbreaks (Wang et al., 2005a; Todd, 2017; Rahman and Sarkar, 2019).

There is reasonable evidence to suggest that SARS-CoV-2 can replicate in the GI tract. Firstly, the GI tract contains an abundance of the metallopeptidase, angiotensin-converting enzyme 2 (ACE-2) which is the cell surface functional receptor (attachment site) for SARS-CoV-2 (Bertram et al., 2012; Li et al., 2020c). Secondly, it has been shown *in vitro* that HCoV-229E and SARS-CoV-2 can infect cells from the respiratory, gastrointestinal, hepatic and central nervous systems. Studies have indicated that SARS-CoV-2 has a 10–20 times greater affinity to ACE-2 receptors compared to SARS-CoV-1, with a potentially lower infectious dose (Galbadage et al., 2020; He et al., 2020b). It has been shown that the ACE-2 receptor protein is highly expressed not only in lung cells but also in esophageal epithelial cells and absorptive enterocytes (epithelial cells) present in the stomach, duodenum, ileum, colon and rectum (Xiao et al., 2020b; Li et al., 2020c; Zhang et al.,

2020; Guo et al., 2020b; Zang et al., 2020). Further, ACE-2 mRNA transcripts have been reported to be more abundant in intestinal cells than in lung tissues (Du et al., 2020b). Its expression in the small intestine has also been found to increase with age suggesting that it may help explain the increased severity of symptoms in elderly patients (Vuille-dit-Bille et al., 2020). The ACE-2 receptor is also present in the kidney and bladder, suggesting the potential for viral replication in the urinary system (Du et al., 2020b; Li et al., 2020c; Martinez-Rojas et al., 2020) and potentially explaining the subsequent recovery of SARS-CoV-2 in urine (Ling et al., 2020). This is supported by autopsies of SARS-CoV-1 confirmed patients where presence of the virus has been demonstrated in tubular epithelial cells (Diao et al., 2019; Su et al., 2020b). Gastrointestinal tissue samples obtained from esophageal, esophageal non-lesion, gastric, duodenum and rectum mucosa have also tested positive for the presence of SARS-CoV-2 in clinical cases (Xiao et al., 2020b).

Once in the GI tract, the spike (S) protein, which is abundant in the viral lipid membrane, induces binding of the virus to the ACE-2 receptor on the host cell surface, the main point of cell entry (Tian et al., 2020). The S glycoprotein has two key functional domains, S1 and S2. S1 contains the receptor-binding domain, which directly binds to the peptidase domain of ACE-2, whereas S2 is responsible for binding to the cell membrane (Mönkemüller et al., 2020). These two domains need to become physically separated to induce cell binding (i.e. activated). This process is initially mediated by the host cell protein convertase, furin, which acts on the S1/S2 site to break open the S protein structure to allow simultaneous binding to the ACE-2 receptor (via S1) and cell membrane (via S2; Bestle et al., 2020). This activation process is further facilitated by the host's type II transmembrane mucosa-specific serine protease (TMPRSS2) which acts on the S2' domain to release the fusion peptide. TMPRSS2 is highly expressed in the lung, kidney, bladder, small intestine and colon relative to other tissues (Paniri et al., 2020). Fusion and subsequent entry of the viral genetic material into the host cell then occurs (Fig. 4; Hoffmann et al., 2020; Mönkemüller et al., 2020). Estimates suggest that this process takes from 10-15 min to complete (Ng et al., 2003).

298 In addition to TMPRSS2, another mucosa-specific serine protease, TMPRSS4, also appears to
299 enhance fusogenic activity and viral entry into the host cell (Zang et al., 2020). Once inside the cell,
300 the uncoated viral RNA with 5' cap structure and 3' poly (A) tail, acts like mRNA, facilitating rapid
301 translation of the replicase polyproteins (Pal et al., 2020). Once complete, viral replication
302 proceeds, followed by RNA packing and envelope packaging as described in detail elsewhere (Guo
303 et al., 2020a; Boopathi et al., 2020). The replicated virions are then released from the cell via
304 exocytosis (i.e. continual budding rather than cell bursting) back into the GI tract to infect other
305 cells (da Costa et al., 2020). This eclipse period (i.e. time taken from adsorption into the cell to the
306 subsequent release of infectious progeny) is estimated to be 7-8 hours (Harcourt et al., 2020;
307 Schneider et al., 2012). Although not known for SARS-CoV-2, based on other viruses, each cell
308 may produce up to 10^2 - 10^3 virions (Hirano et al., 1976). Given the number of epithelial cells with
309 ACE-2 receptors in the GI tract, even a mild infection may therefore lead to a rapid multiplication
310 of SARS-CoV-2, with the potential to produce a high abundance of viral RNA in fecal matter. Once
311 released, however, the survival of these virions may be extremely low. For example, it has been
312 shown that vesicular stomatitis virus chimeras expressing SARS-CoV-2 spike protein are rapidly
313 inactivated by human colonic fluids with viral titers decreasing 100-fold in 1 hour (Zang et al.,
314 2020), however experiments using wild type SARS-CoV-2 are required to validate this finding.
315 That said, this may help to explain why the capacity to recover infectious virus from stool
316 specimens of COVID-19 patients is highly variable. It is also possible that transit time through the
317 GI tract (i.e. greater in diarrhea cases; Roy et al., 1991) and pre-existing GI conditions (e.g. Crohn's
318 disease, ulcerative colitis; An et al., 2020) may influence viral recovery in feces. This potentially
319 poor survival contrasts with other human enteric viruses that primarily spread via the fecal-oral
320 route (e.g. norovirus, rotavirus) and which are capable of withstanding the harsh environment in the
321 GI tract, including the low pH of gastric fluids, bile and digestive enzymes in the small intestine

and exposure to multiple bacterial by-products (Zang et al., 2020; Tung-Thompson et al., 2014) (Table 1).

In mild COVID-19 infections, no significant damage to the mucous epithelium of esophagus, stomach, duodenum and rectum cells has been reported (Xiao et al., 2020b). However, it is also clear that severe infection can result in prolonged diarrhea and inflammation of the GI tract in a significant proportion of clinical cases (Fig. 1). Although tissue and organ damage may be precipitated by the body's immune response to SARS-CoV-2 infection (leading to the 'cytokine storm', viral sepsis and organ failure)(di Mauro Gabriella et al., 2020; Li et al., 2020d), it might also be caused by direct viral attack of absorptive enterocytes which can induce diarrhea by destroying the cells resulting in malabsorption, unbalanced intestinal secretion and activated enteric nervous system (Tian et al., 2020; Zhang et al., 2020c). This is similar to that seen in porcine epidemic diarrhea (corona)virus (PEDV) infections where widespread histopathological damage to enterocytes occurs (Jung et al., 2014).

The role of the gut microbiome in the potential colonization of the GI tract by SARS-CoV-2 remains unknown. Evidence from the upper respiratory tract, however, suggests that some commensal bacteria in the mucosal biofilm (e.g. **Proteobacteria**) express proteins which can bind to the viral S-protein. This may prevent viral interactions with cell surface ACE-2 receptors and which may help prevent severe infections from developing (i.e. bacterial decoys; Honarmand Ebrahimi, 2020). Whether this occurs in the GI tract remains unknown, however, it should be noted that the overabundance of Proteobacteria in the GI tract is normally associated with dysbiosis (Shin et al., 2015; Rizzatti et al., 2017). It should also be noted that microbial diversity in the GI tract decreases with age, leading to suggestions that this may play a role in increased disease severity in elderly and type-II diabetic patients (Dhar and Mohanty, 2020; Gurung et al., 2020). It does suggest that further investigations of the gut microbiome are needed to establish its role in viral infection and the development of symptoms. Ultimately, this may also lead to the development of therapies to reduce

the severity of COVID-19 (Kalantar-Zadeh et al., 2020). For example, fecal transplants have been considered as a treatment for critically ill COVID-19 patients, however, the success of such interventions remains unknown (Thalanayar Muthukrishnan and Faillace, 2020). Alternatively, changes in diet and the use of probiotics/prebiotics have also been proposed as a strategy to build immunity and reduce disease severity in the GI tract (Dhar and Mohanty, 2020; Ranjbar et al., 2020).

5. Levels of SARS-CoV-2 in urine and feces

A range of PCR-based technologies (e.g. RT-qPCR, digital PCR) are available to quantify the amount of SARS-CoV-2 RNA present in tissue, fluid and stool samples with very high sensitivity (≤ 10 gc in a sample). These assays typically target genes encoding the S, E and N structural proteins, the RdRp gene which encodes the RNA-dependent RNA polymerase or the replicase protein ORF1ab gene (van Kasteren et al., 2020). These quantitative assays, however, also have limitations that must be considered. For example, differences in sensitivity can occur depending on the PCR primer and probe sets used (Jung et al., 2020; Pillonel et al., 2020). Poor sensitivity and PCR inhibitors in fecal material (e.g. bile salts, lipids) may also lead to underestimation of viral abundance, or the reporting of false negatives (Schrader et al., 2012). Loss of viral signal during sample pre-treatment (e.g. heat inactivation) may also occur (Pan et al., 2020a). Further, the lack of extraction controls (i.e. surrogate CoVs to look at viral recovery from the sample) may lead to underestimates of viral abundance. The lack of standards has meant that only semi-quantitative results (i.e. Ct values) have been reported in most early studies, especially those examining the temporal dynamics of viral shedding. Lastly, these Ct values vary between platform, gene target assay, and template concentrations used, which causes issues of comparability between studies (Seong et al., 2016; Rahman et al., 2020). These issues seem to be most apparent in samples with high Ct values ($Ct \geq 34$; Lowe et al., 2020). It is also important to state that quantification of viral

RNA by RT-qPCR or digital PCR does not necessarily equate to infectious viral particles (Atkinson and Petersen, 2020), as it is likely that a large proportion of viral particles are damaged during passage through the GI tract and are thus non-infectious (Pfeiffer, 2010; Zhou et al., 2017; Zang et al., 2020). Despite these limitations, there is strong evidence to suggest that feces contain high viral RNA loads. For example, one study has shown that levels of SARS-CoV-2 RNA in stools can range from 5.5×10^2 to 1.2×10^5 copies/ml (Pan et al., 2020b), while another has reported levels of 6×10^5 to 7×10^6 gc/ml in three patients (Zang et al., 2020) and two studies reporting fecal shedding of up maximum of 1.0×10^7 gc/ml (Han et al., 2020; Wölfel et al., 2020). This wide variation in fecal viral RNA load (10^2 - 10^7 gc/ml) reflects differences in the severity of disease between patients and also the temporal dynamics of the disease (To et al., 2020b). It should be noted, however, that the abundance of SARS-CoV-2 RNA in feces are much lower than for other non-enveloped enteric viruses, such as norovirus (ssRNA virus; 10^8 to 10^{10} /g; Lai et al., 2013; Lee et al., 2007), rotavirus (dsRNA virus; up to 10^9 /g; Bennett et al., 2019) and adenovirus (dsDNA virus; 10^6 to 10^{11} /g; Srinivasan et al., 2015).

In comparison with feces, at the peak of infection, levels of SARS-CoV-2 in saliva have been shown to typically range from 10^3 to 10^8 gc/ml with averages of 3.3×10^6 gc/ml (To et al., 2020a), 5.7×10^5 gc/ml (To et al., 2020b), 8.4×10^6 gc/ml (Yoon et al., 2020) and 5.0×10^5 gc/ml (Han et al., 2020). Analysis of nasopharyngeal fluid has reported values ranging from 6.4×10^2 gc/ml to 1.3×10^{11} gc/ml (median of 8.0×10^4 in throat samples and 7.5×10^5 in sputum samples)(Han et al., 2020; Pan et al., 2020b; Yoon et al., 2020), while others have reported viral loads ranging from 10^6 to 10^8 gc/ml in pharyngeal mucosa and endotracheal aspirate (To et al., 2020b; Fitzek et al., 2020). This implies that swallowing of sputum, saliva and nasopharyngeal fluids may contribute to the fecal SARS-CoV-2 RNA signal in some individuals. However, the fact that SARS-CoV-2 RNA cannot be found in feces from all infections (i.e. nasopharyngeal positive, fecal negative) suggests that its contribution might be small.

There are few reports of SARS-CoV-2 RNA in urine as this is not a common manifestation of COVID-19, even in severe infections (Lo et al., 2020; Wang et al., 2020; Wölfel et al., 2020); however, one study has reported levels of 3.2×10^2 gc/ml (Peng et al., 2020b) and in another a very short-lived peak of 6.1×10^5 gc/ml (Yoon et al., 2020). It should be noted that most of the reports of viral loads are for hospitalized patients with mild to severe COVID-19 symptoms and that this may not accurately reflect viral abundance in asymptomatic, pre-symptomatic or very mild cases where levels in feces are likely to be much lower. It is also expected that renal infections will not occur in these mild or asymptomatic cases, suggesting that urine is not a vehicle for disease transmission outside of clinical settings, or at all.

The between-person variability in viral load, even within severe cases, appears to be very large (To et al., 2020b). This likely reflects the wide variation in symptoms experienced by individuals and organs targeted by the virus (Fig. 1). Overall, evidence suggests that high levels of SARS-CoV-2 RNA in feces is consistent with a GI tract infection in some individuals. However, the possibility that GI tract symptoms in COVID-19 cases are caused by other organisms cannot be discounted. For example, antibiotics are often prescribed during treatment of severely ill patients, creating a niche for opportunistic GI bacterial pathogens, and has been directly linked to the incidence of diarrhea in some COVID-19 studies (Lin et al., 2020). Accumulating evidence also indicates that microbial co-infection may increase the risk of disease severity in humans by suppression of the immune system or by overcoming antibiotics used in disease therapies (Zhu et al., 2020). The evidence on co-infections on the outcome of COVID-19 patients appears contradictory (Pinky and Dobrovolny, 2020). What is clear, however, is that co-infections are commonplace. For example, an analysis of nasopharyngeal swabs showed that 20% of the individuals ($n = 116$), who tested positive for SARS-CoV-2 also tested positive for other respiratory pathogens (Kim et al., 2020). The most common co-infections being rhinovirus/enterovirus (6.9%), respiratory syncytial virus (5.2%), and non-SARS-CoV-2 coronaviridae (4.3%). Similarly, Zhu et

al. (2020) found that 32% had viral co-infection, 92% had bacterial co-infection, and 23% had fungal co-infections with respiratory pathogens. This level of co-infection is similar to other HCoV strains (Gaunt et al., 2010). A similar study reported co-infection of the respiratory tract by SARS-CoV-2 and influenza A and B (Ding et al., 2020a). Similar work is therefore required to determine the level of co-infections in the GI tract, especially as this might impact on the severity of infection by SARS-CoV-2. The quantities of SARS-CoV-2 RNA in feces are also within the range reported for other respiratory viruses such as influenza H1N1 (swine flu) which has been detected in respiratory, stool, and urine samples at levels of 2.7×10^9 , 7.2×10^6 , and 7.24×10^4 copies/ml, respectively (To et al., 2010), and in the case of MERS-CoV where levels in urine ranged from 10^2 - 10^3 gc/ml, feces from 10^3 - 10^4 gc/ml and those in the respiratory tract from 10^6 - 10^7 gc/ml (Corman et al., 2015; Drosten et al., 2013) (Fig. 3). In contrast, the levels of SARS-CoV-1 in feces, however, has been reported to be much higher than for SARS-CoV-2, ranging from 10^3 - 10^9 gc/ml (Cheng et al., 2004; Hung et al., 2009). This latter result suggests that conclusions on fecal-oral transmission risk from SARS-CoV-1 should be extrapolated to SARS-CoV-2 with extreme caution.

6. Is SARS-CoV-2 in stool and urine infectious?

Of critical concern in evaluating the risk of a fecal/urine-oral or fecal/urine-ocular transmission pathway for SARS-CoV-2 is the degree of infectivity of fecal- and urine-derived virus particles. These studies require tissue culture with human (or other) cell lines where addition of SARS-CoV-2 leads to an increase in viral titer from 10^2 particles/ml in the culture medium to 10^6 particles/ml within 12 hours (Lamers et al., 2020; Matsuyama et al., 2020; Ogando et al., 2020). One of the first infectivity studies was undertaken from stool samples taken from a laboratory-confirmed COVID-19 severe pneumonia case, 15 days after the onset of symptoms. After viral isolation, VERO cell cultures were inoculated and virus multiplication was subsequently detected, suggesting that feces have the potential to transmit the disease (Zhang et al., 2020d). In a subsequent, more

comprehensive study of COVID-19 cases, it was found that of the 153 stool specimens analyzed, 29% tested positive for SARS-CoV-2, from which infectious virus was recovered from 2 samples (Wang et al., 2020c). Similar studies have also confirmed the recovery of infectious virus from stools, VERO cells and human in intestinal organoid cultures (Lamers et al., 2020; Xiao et al., 2020a; Zhou et al., 2020).

Other comprehensive studies have suggested that no infectious viral particles can be recovered from feces at the peak of infection, despite infectious virus being recovered from respiratory specimens (Wölfel et al., 2020). The recent isolation of infectious virus from urine raises the possibility for urine-based transmission (Sun et al., 2020a), although given the low prevalence of this phenomenon, its significance outside of clinical settings is probably extremely low. Although these studies confirm that feces and urine may contain infectious viral particles, they also have various drawbacks. Firstly, it is evident that while viral recovery is possible from some samples, interestingly it is not from others, despite all the feces testing RT-qPCR or digital PCR positive for SARS-CoV-2 RNA. Similar observations have also been made for nasopharyngeal swabs from patients with lower viral load, suggesting viral nucleic acids might be detected for longer periods than the live virus in different sample types (NCIC-AMS, 2020). In addition, studies have only focused on feces with high viral loads (based on Ct values) and these may not be reflective of pre- or asymptomatic cases. The levels of SARS-CoV-2 RNA in the samples used in these infectivity assays are also not reported, preventing realistic quantitative risk assessments to be made for fecal/urine-oral transmission (and to account for the levels added in the source material itself). The lack of inclusion of positive controls is also problematic where no infectious virus is recovered from any samples; i.e. problems with local culturing protocols cannot be eliminated (Wang et al., 2005b). Further, in plaque-based assays, co-contaminating (non-CoV) viruses may also lead to false-positive results, although metagenomics could be used to identify this. In such cases, it is essential that a quantitative increase in SARS-CoV-2 beyond the inoculum dose is

confirmed by qPCR. It would also be advantageous to undertake dose response curves (i.e. serial dilution of fecal extracts) to allow determination of comparative levels of infectivity between samples with known viral titers (Matsuyama et al., 2020). Further, the virus is known to propagate poorly in some cell lines currently being used to assay the infectivity of SARS-CoV-2 (Harcourt et al., 2020; Matsuyama et al., 2020; Ogando et al., 2020). Therefore, it is unclear whether negative infectivity results indicate a lack of infectious particles or just a poor choice of screening assay. Based on this we conclude that further work is needed to better evaluate the temporal dynamics of viral shedding and its infectious nature in feces and urine.

For disease transmission in the community it is important to know whether feces and urine contain infectious virus in the pre- and post-symptomatic phase. This is particularly pertinent given that clinical cases may still be shedding the virus after the relieving of symptoms and their discharge back into the community. However, current evidence suggests that the infectious viral count will decline rapidly within a week of symptoms starting. Drawing on evidence from nasopharyngeal samples, which has shown a close correlation between viral abundance and infectivity, it is likely that viral shedding in feces in the post-symptomatic phase poses a much lower transmission risk (La Scola et al., 2020; Wölfel et al., 2020). In addition, even if infectious virus is detected in cell culture, it doesn't necessarily imply that it will cause infection in the upper respiratory tract of humans at the same dose, as physicochemical barriers (e.g. mucus, low pH) can further limit virus infectivity (NIS-PHE, 2020).

Overall, we conclude that while virus particles contained in respiratory droplets are known to be highly infectious, evidence suggests that feces and urine probably contain low levels to no infectious particles. In comparison to respiratory particles, they are also less likely to be spread during daily life, being confined largely to toilets and other enclosed environments. This may subsequently lead to contamination of hands, surfaces, food and water; however, in most cases the levels of contamination are likely to be low where good hygiene and sanitation is practiced. Despite

this, the possibility of infection by contamination of the oral cavity, respiratory mucosa and eyes cannot be entirely discounted. This risk of infection spread is most likely associated with those experiencing co-infections or frequent watery diarrhea (Peiris et al., 2003; Tsang et al., 2003). As shedding rates appear to be correlated with symptom severity and the peak of the infection cycle, this risk would be greatest firstly in intensive care units (i.e. nosocomial spread), followed by care facilities (e.g. elderly care homes) where residents with diarrhea need secondary assistance, and heavily used and poorly maintained public toilets. The potential for the virus to spread from domestic toilets is likely to be very low as these have restricted use, probably involve individuals with mild infections and those with the capacity to practice good personal hygiene unassisted. Subsequently, in developing regions, where access to safe and hygienic sanitation is limited, the risks associated with fecal transmission routes may be higher (Anser et al., 2020; Patel, 2020). For example, an estimated 9% (673 million) of the global population defecate in the open and another 8% (627 million) use a facility shared with at least one other household as their primary sanitation location (Caruso and Freeman, 2020). This risk is perceived to be highest in urban sub-Saharan Africa where an estimated 32% of sanitation is shared (UNICEF-WHO, 2019). Further, women might be at increased risk due to more frequent use, both for meeting their own needs, including menstruation, and assisting dependent family members (Caruso et al., 2017). Another exemplar is India, where ca. 15% of households lack access to improved sanitation. The availability of soap for effective handwashing and elimination of SARS-CoV-2 from the face and hands is also problematic in many countries (Patel, 2020; Coetzee and Kagee, 2020). Sanitary workers in less economically developed countries may also be at higher risk of contracting COVID-19, due to underlying respiratory problems associated with exposure to various hazardous materials and lack of personal protection equipment (Salve and Jungari, 2020).

The survival of SARS-CoV-2 in feces after release from the body is poorly understood. However, this information is important to evaluate the potential for environmental transmission.

The fecal-oral route has also been implicated in disease transmission during sexual contact, however, this risk is believed to be very low in comparison to disease transmission via respiratory droplets and the oral-oral route (Pan et al., 2020c; Cui et al., 2020; Li et al., 2020e). From the available evidence on SARS-CoV-1 it has been shown that the virus can survive for 3 hours to 5 days depending on the watery nature of the diarrhea (positively related to water content), but numbers fall exponentially with time and survival rate is less than in nasopharyngeal or tracheal aspirate (Chan et al., 2004; Lai et al., 2005). More work is needed to understand the factors that influence the survival of fecal-derived SARS-CoV-2 on different matrices after release (e.g. bed sheets, towels, clothes, toilets).

7. Persistence of SARS-CoV-2 in sanitation facilities

One of the most likely points of disease transmission from feces and urine is via shared toilets (e.g. hospitals, workplaces). Based on the use of surrogate viruses and 10^6 viral particles per fecal event, work has shown that is unlikely that SARS-CoV-2 would reach high levels on contact surfaces via the aerosol route after flushing (e.g. $<10^3$ particles on either the seat, handle, floor, walls)(Sassi et al., 2018). In contrast, repeated use by people infected by SARS-CoV-2 might lead to a progressive accumulation of virus to higher levels, assuming infrequent cleaning. This is supported by studies in a dedicated SARS-CoV-2 outbreak center in Singapore where SARS-CoV-2 RNA was recovered from the toilet bowl, sink and door handle (Ong et al., 2020). Another study also found elevated levels of the virus in a patient-dedicated mobile toilet in China (Liu et al., 2020d), while others have detected contamination of toilet seats, exhaust grilles and taps in a COVID-19 dedicated hospital (Ding et al., 2020b; Chia et al., 2020) and in households (Döhla et al., 2020). The source of contamination could have been from urine and feces in the toilet, particularly in facilities used by patients with diarrhea (Chia et al., 2020). This spread is likely to be highly dependent on the

operational design of the toilet (Li et al., 2020f). It is also likely that contamination on touch surfaces and walls was caused via respiratory droplets during coughing, or from transfer to surfaces from hands contaminated with nasopharyngeal fluids. Although each episode of diarrhea or vomit may spread low levels of virus, patients with GI symptoms often have several/frequent episodes of these symptoms, potentially increasing the virus load on those surfaces.

Vomiting also has the potential to spread the virus more widely than either defecation or urination events (i.e. vomiting onto floors, toilets and sinks) due to the greater potential for droplet formation and aerosolization (Kirby et al., 2016; Makison Booth and Frost, 2019). For example, projectile vomit can contaminate an area of up to 8 m² (Makison Booth, 2014). Unfortunately, the levels of infectious SARS-CoV-2 in vomit remain unknown, but are likely to be low based on the low pH of vomit (mean pH of 3.8, range 2.5-5.0) and studies in other CoVs (Kirby et al., 2016; Willumsen et al., 2004; Cowen and Hitchner, 1975; Panon et al., 1988). Vomit is also likely to contain SARS-CoV-2 from nasopharyngeal fluids as well as from the GI tract. The potential for vomit-, fecal- and urine-derived SARS-CoV-2 to remain infectious on sanitation surfaces for long periods of time remains unclear and is probably highly dependent on the receiving surface (toilet bowl, walls, floor etc), prevailing climatic conditions (e.g. temperature, humidity, UV exposure; Ren et al., 2020), and cleaning regime (Kampf et al., 2020). Studies on other matrices, however, have shown that viable SARS-CoV-2 might persist for at least 3 hours in aerosols after their formation (Smither et al., 2020), and for up to 2 or 4 days on plastic and stainless steel surfaces (van Doremalen et al., 2020; Chin et al., 2020). This has led to guidance suggesting that toilets in communal areas should be disinfected with sodium hypochlorite or other virucidal disinfectants at least daily (ECDC, 2020). In conclusion, there is evidence to suggest that viral contamination of toilet environments may occur, although levels of contamination are expected to be very low in most settings based on infectious viral loads in feces and urine. An exception to this could be very high occupancy toilets where a progressive accumulation of the virus may occur, no sanitary

cleaning is undertaken, and personal hygiene practices are poor. Although we cannot discount the potential for fecal-mucosal transmission when individuals touch their mouth, nose or eyes with contaminated hands, this would be largely preventable through handwashing and regular disinfection of sanitation facilities.

The discussion above mainly relates to countries with good levels of domestic sanitation; however, over 2.5 billion people worldwide lack access to improved water and sanitation (e.g. urban slums, rural locations, refugee camps)(Sommer et al., 2015). In these settings, infection control may be more challenging due to the lack of handwashing facilities and cultural issues (e.g. gender violence; Poole et al., 2020; Sommer et al., 2015; Truelove et al., 2020). Additionally, existing toilet and sanitation facilities tend to be less private, which leads to greater personal congregation near central facilities. Similar is true for community potable water sources, which often are only in a handful of locations, such as community water taps, for whole neighborhoods. To date, very little is known about the persistence and infectivity of SARS-CoV-2 in these contexts and further work is clearly needed in this area.

8. Amount and persistence of SARS-CoV-2 in the sewer network

Once feces and urine enter the sewer network there are several points at which human exposure may occur (Fig. 5). However, significant dilution will occur in the drainage network due to inflow of water from other domestic and industrial sources. For example, at the peak of a severe infection, based on our analysis, an adult may be expected to lose ca. 1.0 l of fluid in diarrhea (during 3-6 events) and 0.8 l in urine per day (Aranda-Michel and Giannella, 1999; Pan et al., 2020d). Assuming a SARS-CoV-2 load of 8×10^6 gc/ml in feces and 3.2×10^2 gc/ml in urine and a flushing volume of 6.8 l per defecation/urination event (6 per d), this equates to a viral concentration in water leaving the toilet of 1.9×10^8 gc/l. In a single occupancy household setting, and assuming a total water use of 135 l/person/d, this will be further diluted, giving a maximum final effluent

concentration of 5.9×10^7 gc/l and total viral excretion load of 8.0×10^9 gc/person/d. It is important to note that these calculations are based on genome copy numbers, which are significantly higher than infectious virus particle numbers, due to the production of defective viral genomes during RNA virus replication (Vignuzzi and López, 2019). Studies of wastewater have yet to recover infectious virus, despite its genetic material being readily detected by PCR (Döhla et al., 2020).

The human minimal infectious dose of SARS-CoV-2 is not currently known. Estimates for SARS-CoV-1 range from 16 to 280 plaque forming units (PFU)(Watanabe et al., 2010). Unfortunately, the relationship between genome copies and PFU is also unknown for SARS-CoV-2, however, it is interesting to note that viable SARS-CoV-2 could not be isolated from clinical respiratory tract samples containing fewer than 10^6 gc/ml (Wölfel et al., 2020). For influenza virus, the ratio between TCID₅₀ (TCID₅₀ = PFU/0.7) and particle count is 1:100 to 1:1000 (Yezli and Otter, 2011), whilst work with clinical influenza samples has demonstrated a 100-10,000 fold difference between TCID₅₀ and genome copy number (Van Wessenbeeck et al., 2015). On this basis, it is likely that the human minimal infectious dose of aerosolized SARS-CoV-2 is in the order of 10^3 - 10^4 gc. The route of infection is also critical when considering the infectious dose. In influenza, the infectious dose of aerosolized virus appears to be several orders of magnitude lower than for virus that is deposited in droplets on the upper respiratory tract (Yezli and Otter, 2011). The infectious dose of SARS-CoV-2 if transmitted via the feco-oral route is therefore likely significantly higher than 10^3 - 10^4 gc. On this basis, exposure to raw sewerage from an infected household, elderly care home, or medical center could theoretically pose a small infection risk to sanitation workers, assuming the virus is still infectious. Parallels from SARS-CoV-1 investigations can also be drawn here. In the classic Amoy Gardens case study, raw sewage from one household entered vertically connected neighboring households, resulting in a localized infection hotspot (McKinney et al., 2006; Yu et al., 2014; Stein, 2011). It should be noted, however, that this sanitation network was poorly maintained and would not represent those in most municipal

buildings and should not be used to infer the risk of fecal-oral transmission of SARS-CoV-2. Furthermore, transmission in the Amoy Gardens case study was believed to be via the aerosolization and inhalation of infectious fecal matter, rather than via the feco-oral route.

Beyond the immediate point of entry into the sewer system point, the wastewater will be further diluted in the drainage network by the addition of sewerage from non-infected households. At the peak of infection in the UK in April 2020, it was estimated that 0.25% of the population was infected (ONS, 2020). This would equate to an average community sewerage load of 1.75×10^5 gc/l reaching a centralized wastewater treatment plant. This is consistent with typical concentrations being reported in wastewater in many regions of the world ranging from 10^2 to 10^6 gc/l (Ahmed et al., 2020; Foladari et al., 2020; Randazzo et al., 2020; Wu et al., 2020b; Wurtzer et al., 2020ab). At present, there are many uncertainties in the survival of SARS-CoV-2 during its passage through the sewer pipe network. CoVs are not thought to survive well in aqueous environments, especially in comparison with other viruses which can persist for months (e.g. poliovirus, norovirus; Seitz et al., 2011). This is supported by studies in which SARS-CoV-2 RNA can be readily detected by qPCR in wastewater leaving hospitals, but which has yet to be found to contain infectious virus (Wang et al., 2005b; Zhang et al., 2020e; Wang et al., 2020d). In fact, a recent study suggests that levels of infectious virus were not significant in wastewater and receiving rivers, indicating the effectiveness of wastewater treatment, combined with the natural loss of viral integrity (Rimoldi et al., 2020). Additionally, viral particles are likely to become bound to biofilms in the pipes, degraded by other microorganisms and inactivated by xenobiotics (e.g. surfactants, disinfectants), all of which will lead to a progressive loss of qPCR RNA signal and degrade infectious virus (if any is present at all)(Cheng et al., 2004; Wigginton et al., 2015). However, when SARS-CoV-1 was inoculated into sewage at high titers (10^5 - 10^6 gc/l) it was found to still contain infectious material after 14 days at 4°C and 2 days at 20°C (Wang et al., 2005c). These conflicting laboratory and field-based studies may reflect the different nature of the starting inoculum and failure of the lab conditions to reflect

those in the field. This, however, may suggest that, if any live virus is present in the wastewater, some could survive during passage through the sewage network, based on typical transit times from households to the wastewater treatment plant (1 to 24 h). Current evidence suggests that the levels of SARS-CoV-2 are greatly lowered during wastewater treatment, suggesting that the virus is either degraded or becomes associated with the solids fraction during flocculation (Wang et al., 2020d). This is consistent with studies showing a 2 to 3 log₁₀ removal efficiency in viral RNA abundance when comparing viral levels in influent and effluent (Wurtzer et al., 2020) and the accumulation of SARS-CoV-2 in the sludge fraction (Peccia et al., 2020; Alpaslan Kocamemi et al., 2020). If the sludge (biosolids) fraction is treated (e.g. pasteurized, heat-dried, alkali-lime treated), as per the legislative requirement in many countries, this should pose no further risk to human health. One potential area where a heightened risk of exposure may occur is during the release of bioaerosols from wastewater aeration tanks. However, based on current estimates of the infectious dose of SARS-CoV-2, the likelihood that this poses a risk to workers is extremely low based on the amount of sewage that would need to be inhaled by this route to cause infection (assuming appropriate use of personal protection equipment). In addition, there is no evidence to suggest that wastewater plant operatives are at any greater risk to SARS-CoV-2 exposure via this route than that of the general population, particularly when standard issue personal protective equipment is worn (WHO, 2020). In theory, it is possible that local residents can be exposed to bioaerosols emitted from wastewater plants (Brisebois et al., 2018; Yang et al., 2019), however, there are few documented examples where direct viral transmission has been linked back to a wastewater treatment facility. In the case of SARS-CoV-2, parallels should not be drawn with other viruses (e.g. norovirus, rotavirus) whose concentrations in wastewater are typically much higher (Pasalari et al., 2019).

9. Amount and persistence of SARS-CoV-2 in the wider environment

Given the reduced evidence on infectious virus in sewers at present and the possible degradation and treatment processes explained above, detection in the wider environment most likely reflects viral RNA, not infectious virus. Based on the available evidence and our own measurements, the quantity of SARS-CoV-2 RNA in the effluent from wastewater treatment plants at the peak of a community infection ($< 0.5\%$ of the total population) is unlikely to exceed 10^4 gc/l (Wurtzer et al., 2020). Assuming that levels of viral infection decline in the community due to the implementation of successful control measures (e.g. ‘lock down’ and social distancing) then levels in wastewater are expected to fall below $<10^2$ gc/l. Based on the large dilutions of treated wastewater after discharge into adjacent freshwaters (ca. 5-100 fold dilution under low river flow conditions when the risk is greatest) or the coastal zone (ca. 10^5 fold dilution), it is highly likely that SARS-CoV-2 will pose very little threat to human health (e.g. during watersports, bathing, angling, consumption of shellfish etc; Keller et al., 2014). This is supported by measurements of typical levels of water ingestion during recreational activities of 3-30 ml/person in rivers and lakes (Dorevitch et al., 2011), 34 ml/person during surfing (Stone et al., 2008), and 10-50 ml/person during swimming and bathing (Dufour et al., 2017; Schets et al., 2011). Assuming a worst case human feco-oral infectious dose of 10^3 gc/person, this would necessitate that levels of infectious SARS-CoV-2 greater than 3.3×10^4 gc/l would be needed to cause concern. It should also be noted that while the eyes are often in contact with water during recreational activities, this route of SARS-CoV-2 entry into the body is thought to be minimal, particularly in comparison to ingestion of water and oral/nasopharynx mucosal exposure (Sun et al., 2020b; Deng et al., 2020). This analysis for SARS-CoV-2 contrasts with other viruses transmitted by the fecal-oral route (e.g. norovirus) where the infectious dose is very low (ca. 10 viral particles), levels in wastewater are higher and water-borne outbreaks have been reported (Parkkali et al., 2017 Russo et al., 2020).

In comparison to wastewater entering waterbodies, a greater source of potential risk to infection could be the presence of an infected individual within the water itself. It is likely that

during swimming, a person may release ca. 30-60 ml of saliva into the water (Bretz and Carrilho, 2013). Contamination may also occur from ocular fluids (Güemes-Villahoz et al., 2020). Given the highest recorded levels of virus in saliva (10^8 gc/ml), a swimming volume of 375,000 l ($25 \times 10 \times 1.5$ m), then the levels of SARS-CoV-2 in the water would be 1.2×10^4 gc/l. Assuming the inadvertent ingestion of 20 ml by an individual during swimming, this would result in a SARS-CoV-2 exposure dose of 2.4×10^2 gc/person. This risk would be most relevant in non-chlorinated waters as standard disinfection procedures (e.g. chlorination and UV treatment in swimming pools) should rapidly reduce levels of infectious virus in the water (WHO, 2020). It should be noted that natural UV irradiation is also likely to eliminate the virus in water (Lytle and Sagripanti, 2005), however, the effect of this on SARS-CoV-2 in aqueous media remains unknown. Work on aerosolized SARS-CoV-2 has shown that it is inactivated relatively quickly (within hours) by solar UV irradiation (Sagripanti and Lytle, 2020). Further work is required to model the dispersal of SARS-CoV-2 in a range of aqueous environments (e.g. lidos, swimming pools, rivers, estuaries, coastal waters). Fundamental to this is a better knowledge of (i) the persistence and infectivity of SARS-CoV-2 in these environments, (ii) the potential for zoonotic infection (secondary hosts for SARS-CoV-2), and (iii) establishing the infectious dose of the virus. Using these data, and currently known information on SARS-CoV-2, quantitative microbial risk assessments could be undertaken to inform on human health risks in different environmental exposure scenarios based on dose-response models (Beaudequin et al., 2015).

Unlike other viruses (e.g. norovirus), there is no evidence to suggest that SARS-CoV-2 can accumulate in marine and freshwater organisms destined for human consumption (e.g. fish, oysters, mussels). The low likelihood of SARS-CoV-2 accumulation in fish is supported by the low levels of ACE-2 receptors in these organisms (Damas et al., 2020). In the case of shellfish, it is known that norovirus readily accumulates in shellfish as it binds to a human-like intestinal type A histo-blood group antigen in the shellfish tissue (Tian et al., 2007). Evidence also suggest that oysters

possess an ACE-2-like receptor (CgACE) suggesting that bioaccumulation may be possible, however, whether SARS-CoV-2 can bind to CgACE, and whether the receptor is present in sufficient amounts to induce bioaccumulation remains unknown (Riviere et al., 2011).

10. Conclusions and implications for public health

Our critical analysis of the available evidence and potential transmission routes suggests that the possibility of fecal/urine-oral/ocular transmission of SARS-CoV-2 is extremely low to negligible except where direct person-to-person contact occurs. This is consistent with the many millions of documented cases of COVID-19 worldwide, and the fact that none of these have implicated feces or fecal contaminated material as part of the infection pathway. Feces have been implicated in contamination of the healthcare environment/surfaces, however, the role of those in infection remains unclear. It should be noted that our conclusions are based on western-style sanitation networks and wastewater treatment. The risks may be higher in less economically developed countries and areas with poor sanitation; however, there is insufficient evidence to enable this to be critically evaluated. This is clearly an area that warrants further research. Assuming levels of SARS-CoV-2 remain relatively low in the population (<1%), our analysis also suggests that the risk of contracting COVID-19 from water supplies, wastewater, food, bathing/recreational waters, and the coastal zone remains extremely low. This is particularly the case if personal hygiene measures are maintained (e.g. handwashing) and communal sanitary facilities are regularly cleaned and disinfected (Lotfinejad et al., 2020; Brauer et al., 2020). Following a precautionary principle, we would also recommend that households with an on-going infection, and particularly those exhibiting diarrhea, add sodium-hypochlorite or similar disinfectant prior to flushing to reduce further downstream risk of infection.

Acknowledgements

We thank Neil Dickson, Emily Cooledge (Bangor University) and Andrew Singer (UK Centre for Ecology & Hydrology) for comments on the manuscript and Eadington Graham and Ooid Scientific for the illustrations. This work was funded by the UK Research and Innovation (UKRI) project NE/M009106/1, NE/V004883/1 and NE/V010441/1 under the NERC-COVID-19 programme and the Centre for Environmental Biotechnology Project funded through the European Regional Development Fund (ERDF) by Welsh Government. LSH was supported by a Soils Training and Research Studentship (STARS) grant from the Biotechnology and Biological Sciences Research Council (BBSRC) and Natural Environment Research Council (NE/M009106/1). AC was supported by funding from the Centre of Expertise for Waters (CREW).

Author contributions

DLJ conceived the project and led the writing. All other authors contributed to drafts of the article.

Declaration of interests

All authors declare no competing interests.

References

- Abrams, H.R., Loomer, L., Gandhi, A., Grabowski, D.C., 2020. Characteristics of U.S. nursing homes with COVID-19 cases. *J. Am. Geriatr. Soc.* *in press*.
<https://doi.org/10.1111/jgs.16661>
- Adhikari, S.P., Meng, S., Wu, Y., Mao, Y., Ye, R., Wang, Q., Sun, C., Sylvia, S., Rozelle, S., Raat, H., Zhou, H., 2020. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. *Infect. Dis. Poverty* 9, 29. <https://doi.org/10.1186/s40249-020-00646-x>
- Ahamed Mim, M., Naznin Rakhi, N., Saha, O., Rahaman, M.M., 2020. Recommendation of fecal

specimen for routine molecular detection of SARS-CoV-2 and for COVID-19 discharge
criteria. *Pathog. Glob. Health* 00, 1–2. <https://doi.org/10.1080/20477724.2020.1765651>

Aguila, E., Cua, I., Dumagpi, J., 2020. When do you say it's SARS-CoV-2-associated diarrhea? *J. Gastroenterol. Hepatol. In press*. <https://doi.org/10.1111/jgh.15141>

Ahmed, W., Angel, N., Edson, J., Bibby, K., Bivins, A., O'Brien, J.W., Choi, P.M., Kitajima, M., Simpson, S.L., Li, J., Tschärke, B., Verhagen, R., Smith, W.J.M., Zaugg, J., Dierens, L., Hugenholtz, P., Thomas, K. V., Mueller, J.F., 2020. First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: A proof of concept for the wastewater surveillance of COVID-19 in the community. *Sci. Total Environ.* 728, 138764. <https://doi.org/10.1016/j.scitotenv.2020.138764>

Alpaslan Kocamemi, B., Kurt, H., Sait, A., Sarac, F., Saatci, A.M., Pakdemirli, B., 2020. SARS-CoV-2 detection in istanbul wastewater treatment plant sludges. *medRxiv*. <https://doi.org/10.1101/2020.05.12.20099358>

An, P., Ji, M., Ren, H., Su, J., Ding, N.S., Kang, J., Yin, A., Zhou, Q., Shen, Linyong, Zhao, L., Jiang, X., Xiao, Y., Tan, W., Lv, X., Li, J., Liu, S., Zhou, J., Chen, H., Xu, Y., Liu, J., Chen, M., Cao, J., Zhou, Z., Shen, Lei, Tan, S., Yu, H., Dong, W., Ding, Y., 2020. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China. *Lancet Gastroenterol. Hepatol.* 5, 525–527. [https://doi.org/10.1016/S2468-1253\(20\)30121-7](https://doi.org/10.1016/S2468-1253(20)30121-7)

Andersen, K.G., Rambaut, A., Lipkin, W.I., Holmes, E.C., Garry, R.F., 2020. The proximal origin of SARS-CoV-2. *Nat. Med.* 26, 450–452. <https://doi.org/10.1038/s41591-020-0820-9>

Anser, M.K., Yousaf, Z., Khan, M.A., Nassani, A.A., Alotaibi, S.M., Abro, M.M.Q., Vo, X.V., Zaman, K., 2020. Does communicable diseases (including COVID-19) may increase global poverty risk? A cloud on the horizon. *Environ. Res.* 187, 109668. <https://doi.org/10.1016/j.envres.2020.109668>

Aranda-Michel, J., Giannella, R.A., 1999. Acute diarrhea: A practical review. *Am. J. Med.* 106,

796 670–676. [https://doi.org/10.1016/S0002-9343\(99\)00128-X](https://doi.org/10.1016/S0002-9343(99)00128-X)

797 Assiri, A., McGeer, A., Perl, T.M., Price, C.S., Al Rabeeah, A.A., Cummings, D.A.T., Alabdullatif,
798 Z.N., Assad, M., Almulhim, A., Makhdoom, H., Madani, H., Alhakeem, R., Al-Tawfiq, J.A.,
799 Cotten, M., Watson, S.J., Kellam, P., Zumla, A.I., Memish, Z.A., 2013. Hospital outbreak of
800 middle east respiratory syndrome coronavirus. *N. Engl. J. Med.* 369, 407–416.
801 <https://doi.org/10.1056/NEJMoa1306742>

802 Atkinson, B., Petersen, E., 2020. SARS-CoV-2 shedding and infectivity. *Lancet* 395, 1339–1340.
803 [https://doi.org/10.1016/S0140-6736\(20\)30868-0](https://doi.org/10.1016/S0140-6736(20)30868-0)

804 Beaudequin, D., Harden, F., Roiko, A., Stratton, H., Lemckert, C., Mengersen, K., 2015. Beyond
805 QMRA: Modelling microbial health risk as a complex system using Bayesian networks.
806 *Environ. Int.* 80, 8–18. <https://doi.org/10.1016/j.envint.2015.03.013>

807 Bennett, A., Pollock, L., Jere, K.C., Pitzer, V.E., Lopman, B., Bar-Zeev, N., Iturriza-Gomara, M.,
808 Cunliffe, N.A., 2019. Duration and density of fecal rotavirus shedding in vaccinated Malawian
809 children with Rotavirus gastroenteritis. *J. Infect. Dis.* 1–6. <https://doi.org/10.1093/infdis/jiz612>

810 Bertram, S., Heurich, A., Lavender, H., Gierer, S., Danisch, S., Perin, P., Lucas, J.M., Nelson, P.S.,
811 Pöhlmann, S., Soilleux, E.J., 2012. Influenza and SARS-coronavirus activating proteases
812 TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal
813 tracts. *PLoS One* 7, 1–8. <https://doi.org/10.1371/journal.pone.0035876>

814 Bestle, D., Heindl, M.R., Limburg, H., van, T.V.L., Pilgram, O., Moulton, H., Stein, D.A., Hards,
815 K., Eickmann, M., Dolnik, O., Rohde, C., Becker, S., Klenk, H.-D., Garten, W., Steinmetzer,
816 T., Böttcher-Friebertshäuser, E., 2020. TMPRSS2 and furin are both essential for proteolytic
817 activation of SARS-CoV-2 in human airway cells. *Life Sci. Alliance* 3, e202000786.
818 <https://doi.org/10.26508/lsa.202000786>

819 Boni, M.F., Lemey, P., Jiang, X., Lam, T.T.-Y., Perry, B., Castoe, T., Rambaut, A., Robertson,
820 D.L., 2020. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the

COVID-19 pandemic. bioRxiv 2020.03.30.015008. <https://doi.org/10.1101/2020.03.30.015008>

Boopathi, S., Poma, A.B., Kolandaivel, P., 2020. Novel 2019 Coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. *J. Biomol. Struct. Dyn.* 0, 1–14. <https://doi.org/10.1080/07391102.2020.1758788>

Brauer, M., Zhao, J.T., Bennitt, F.B., Stanaway, J.D., 2020. Global access to handwashing: implications for COVID-19 control in low-income countries. *Environ. Health Perspect.* 128, 057005. <https://doi.org/10.1289/ehp7200>

Bretz, W.A., Carrilho, M.R., 2013. Salivary parameters of competitive swimmers at gas-chlorinated swimming-pools. *J. Sport. Sci. Med.* 12, 207–208.

Brisebois, E., Veillette, M., Dion-Dupont, V., Lavoie, J., Corbeil, J., Culley, A., Duchaine, C., 2018. Human viral pathogens are pervasive in wastewater treatment center aerosols. *J. Environ. Sci.* 67, 45-53. <https://doi.org/10.1016/j.jes.2017.07.015>

Buscarini, E., Manfredi, G., Brambilla, G., Menozzi, F., Londoni, C., Alicante, S., Iiritano, E., Romeo, S., Pedaci, M., Benelli, G., Canetta, C., La Piana, G., Merli, G., Scartabellati, A., Viganò, G., Sfogliarini, R., Melilli, G., Assandri, R., Cazzato, D., Rossi, D.S., Usai, S., Tramacere, I., Pellegata, G., Lauria, G., 2020. GI symptoms as early signs of COVID-19 in hospitalised Italian patients. *Gut* 69, 1547-1548. <https://doi.org/10.1136/gutjnl-2020-321434>

Byrne, A.W., McEvoy, D., Collins, A., Hunt, K., Casey, M., Barber, A., Butler, F., Griffin, J., Lane, E., McAloon, C., O'Brien, K., Wall, P., Walsh, K., More, S., 2020. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases, medRxiv. <https://doi.org/10.1101/2020.04.25.20079889>

Cao, C., Chen, M., He, L., Xie, J., Chen, X., 2020. Clinical features and outcomes of COVID-19 patients with gastrointestinal symptoms. *Crit. Care* 24, 340. <https://doi.org/10.1186/s13054-020-03034-x>

846 Caruso, B.A., Freeman, M.C., 2020. Shared sanitation and the spread of COVID-19: risks and next
847 steps. *The Lancet. Planetary Health* 4, e173. [https://doi.org/10.1016/S2542-5196\(20\)30086-3](https://doi.org/10.1016/S2542-5196(20)30086-3)

848 Caruso, B.A., Clasen, T.F., Hadley, C., 2017. Understanding and defining sanitation insecurity:
849 women's gendered experiences of urination, defecation and menstruation in rural Odisha,
850 India. *BMJ Glob. Health* 2, e000414. <https://doi.org/10.1136/bmjgh-2017-000414>

851 CDC, 2020. COVID-19 Pandemic Planning Scenarios. Centers for Disease Control and Prevention,
852 Atlanta, GA, USA

853 Chan, P.K.S., To, W.K., Ng, K.C., Lam, R.K.Y., Ng, T.K., Chan, R.C.W., Wu, A., Yu, W.C., Lee,
854 N., Hui, D.S.C., Lai, S.T., Hon, E.K.L., Li, C.K., Sung, J.J.Y., Tam, J.S., 2004. Laboratory
855 Diagnosis of SARS. *Emerg. Infect. Dis.* 10, 825–831. <https://doi.org/10.3201/eid1005.030682>

856 Chau, N.V.V., Lam, V.T., Dung, Nguyen Thanh, Yen, L.M., Minh, N.N.Q., Hung, L.M., Ngoc,
857 N.M., Dung, Nguyen Tri, Man, D.N.H., Nguyet, L.A., Nhat, L.T.H., Nhu, L.N.T., Ny, N.T.H.,
858 Hong, N.T.T., Kestelyn, E., Dung, N.T.P., Phong, N.T., Xuan, T.C., Hien, T.T., Tu, T.N.H.,
859 Geskus, R.B., Thanh, T.T., Truong, N.T., Binh, N.T., Thuong, T.C., Thwaites, G., Tan, L.
860 Van, 2020. The natural history and transmission potential of severe acute respiratory syndrome
861 coronavirus 2 infection. *Clinical Infectious Diseases* ciaa711,
862 <https://doi.org/10.1093/cid/ciaa711>

863 Cheng, P.K.C., Wong, D.A., Tong, L.K.L., Ip, S.M., Lo, A.C.T., Lau, C.S., Yeung, E.Y.H., Lim,
864 W.W.L., 2004. Viral shedding patterns of coronavirus in patients with probable severe acute
865 respiratory syndrome. *Lancet* 363, 1699–1700. [https://doi.org/10.1016/S0140-6736\(04\)16255-](https://doi.org/10.1016/S0140-6736(04)16255-7)
866 7

867 Chia, P.Y., Coleman, K.K., Tan, Y.K., Ong, S.W.X., Gum, M., Lau, S.K., Lim, X.F., Lim, A.S.,
868 Sutjipto, S., Lee, P.H., Son, T.T., Young, B.E., Milton, D.K., Gray, G.C., Schuster, S.,
869 Barkham, T., De, P.P., Vasoo, S., Chan, M., Ang, B.S.P., Tan, B.H., Leo, Y.-S., Ng, O.-T.,
870 Wong, M.S.Y., Marimuthu, K., 2020. Detection of air and surface contamination by SARS-

871 CoV-2 in hospital rooms of infected patients. *Nat. Commun.* 11, 2800.
872 <https://doi.org/10.1038/s41467-020-16670-2>

873 Chin, A.W.H., Chu, J.T.S., Perera, M.R.A., Hui, K.P.Y., Yen, H.-L., Chan, M.C.W., Peiris, M.,
874 Poon, L.L.M., 2020. Stability of SARS-CoV-2 in different environmental conditions. *The*
875 *Lancet Microbe* 1, e10. [https://doi.org/10.1016/S2666-5247\(20\)30003-3](https://doi.org/10.1016/S2666-5247(20)30003-3)

876 Cloud, D.H., Ahalt, C., Augustine, D., Sears, D., Williams, B., 2020. Medical isolation and solitary
877 confinement: Balancing health and humanity in US jails and prisons during COVID-19. *J.*
878 *Gen. Intern. Med. in press.* <https://doi.org/10.1007/s11606-020-05968-y>

879 Coetzee, B.J., Kagee, A., 2020. Structural barriers to adhering to health behaviours in the context of
880 the COVID-19 crisis: Considerations for low- and middle-income countries. *Glob. Public*
881 *Health in press.* <https://doi.org/10.1080/17441692.2020.1779331>

882 Corman, V.M., Albarak, A.M., Omrani, A.S., Albarak, M.M., Farah, M.E., Almasri, M., Muth,
883 D., Sieberg, A., Meyer, B., Assiri, A.M., Binger, T., Steinhagen, K., Lattwein, E., Al-Tawfiq,
884 J., Müller, M.A., Drosten, C., Memish, Z.A., 2015. Viral shedding and antibody response in 37
885 patients with Middle East Respiratory Syndrome coronavirus infection. *Clin. Infect. Dis.* 62,
886 477–483. <https://doi.org/10.1093/cid/civ951>

887 Cowen, B.S., Hitchner, S.B., 1975. pH stability studies with Avian Infectious Bronchitis Virus
888 (Coronavirus) strains. *J. Virol.* 15, 430–432. <https://doi.org/10.1128/jvi.15.2.430-432.1975>

889 Cui, P., Chen, Z., Wang, T., Dai, J., Zhang, J., Ding, T., Jiang, J., Liu, J., Zhang, C., Shan, W.,
890 Wang, Sheng, Rong, Y., Chang, J., Miao, X., Ma, X., Wang, Shixuan, 2020. Clinical features
891 and sexual transmission potential of SARS-CoV-2 infected female patients: a descriptive study
892 in Wuhan, China. *medRxiv* 2020.02.26.20028225.
893 <https://doi.org/10.1101/2020.02.26.20028225>

894 da Costa, V.G., Moreli, M.L., Saivish, M.V., 2020. The emergence of SARS, MERS and novel
895 SARS-2 coronaviruses in the 21st century. *Arch. Virol.* <https://doi.org/10.1007/s00705-020->

896 04628-0

897 Damas, J., Hughes, G.M., Keough, K.C., Painter, C.A., Persky, N.S., Corbo, M., Hiller, M.,
898 Koepfli, K.-P., Pfenning, A.R., Zhao, H., Genereux, D.P., Swofford, R., Pollard, K.S., Ryder,
899 O.A., Nweeia, M.T., Lindblad-Toh, K., Teeling, E.C., Karlsson, E.K., Lewin, H.A., 2020.
900 Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2
901 in vertebrates. *bioRxiv* 2020.04.16.045302. <https://doi.org/10.1101/2020.04.16.045302>

902 De Wit, E., Van Doremalen, N., Falzarano, D., Munster, V.J., 2016. SARS and MERS: Recent
903 insights into emerging coronaviruses. *Nat. Rev. Microbiol.* 14, 523–534.
904 <https://doi.org/10.1038/nrmicro.2016.81>

905 Deng, C., Yang, Y., Chen, H., Chen, W., Chen, Z., Ma, K., Wang, J., 2020. Low risk of SARS-
906 CoV-2 transmission through the ocular surface. *Acta Ophthalmol.* 1–2.
907 <https://doi.org/10.1111/aos.14471>

908 di Mauro Gabriella, Cristina, S., Concetta, R., Francesco, R., Annalisa, C., 2020. SARS-Cov-2
909 infection: Response of human immune system and possible implications for the rapid test and
910 treatment. *Int. Immunopharmacol.* 84, 106519. <https://doi.org/10.1016/j.intimp.2020.106519>

911 Diao, B., Feng, Z., Wang, C., Wang, H., Liu, L., Wang, C., Wang, R., Liu, Y., Liu, Y., Wang, G.,
912 Yuan, Z., Wu, Y., Chen, Y., 2020. Human kidney is a target for novel severe acute
913 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. *medRxiv*:
914 2020.03.04.20031120. 10.1101/2020.03.04.20031120.

915 Ding, Q., Lu, P., Fan, Y., Xia, Y., Liu, M., 2020. The clinical characteristics of pneumonia patients
916 coinfecting with 2019 novel coronavirus and influenza virus in Wuhan, China. *J. Med. Virol.*
917 1–7. <https://doi.org/10.1002/jmv.25781>

918 Ding, Z., Qian, H., Xu, B., Huang, Y., Miao, T., Yen, H.-L., Xiao, S., Cui, L., Wu, X., Shao, W.,
919 Song, Y., Sha, L., Zhou, L., Xu, Y., Zhu, B., Li, Y., 2020b. Toilets dominate environmental
920 detection of SARS-CoV-2 virus in a hospital. *medRxiv* 2020.04.03.20052175.

921 <https://doi.org/10.1101/2020.04.03.20052175>

922 Docherty, A.B., Harrison, E.M., Green, C.A., Hardwick, H.E., Pius, R., Norman, L., Holden, K.A.,
923 Read, J.M., Dondelinger, F., Carson, G., Merson, L., Lee, J., Plotkin, D., Sigfrid, L., Halpin,
924 S., Jackson, C., Gamble, C., Horby, P.W., Nguyen-Van-Tam, J.S., Ho, A., Russell, C.D.,
925 Dunning, J., Openshaw, P.J., Baillie, J.K., Semple, M.G., 2020. Features of 20 133 UK
926 patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:
927 prospective observational cohort study. *BMJ* 369, m1985. <https://doi.org/10.1136/bmj>.

928 Döhla, M., Wilbring, G., Schulte, B., Kümmerer, B.M., Diegmann, C., Sib, E., Richter, E., Haag,
929 A., Engelhart, S., Eis-Hübinger, A.M., Exner, M., Streeck, H., Schmithausen, R.M., 2020.
930 SARS-CoV-2 in environmental samples of quarantined households. *medRxiv* 49, 1–19.
931 <https://doi.org/10.1101/2020.05.28.20114041>

932 Dong, Y., Mo, X., Hu, Y., Qi, X., Jiang, F., Jiang, Z., Tong, S., 2020. Epidemiological
933 characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. *J. Emerg.*
934 *Med.* 58, 712–713. <https://doi.org/10.1016/j.jemermed.2020.04.006>

935 Dorevitch, S., Panthi, S., Huang, Y., Li, H., Michalek, A.M., Pratap, P., Wroblewski, M., Liu, L.,
936 Scheff, P.A., Li, A., 2011. Water ingestion during water recreation. *Water Res.* 45, 2020–
937 2028. <https://doi.org/10.1016/j.watres.2010.12.006>

938 Drosten, C., Seilmaier, M., Corman, V.M., Hartmann, W., Scheible, G., Sack, S., Guggemos, W.,
939 Kallies, R., Muth, D., Junglen, S., Müller, M.A., Haas, W., Guberina, H., Röhnisch, T.,
940 Schmid-Wendtner, M., Aldabbagh, S., Dittmer, U., Gold, H., Graf, P., Bonin, F., Rambaut, A.,
941 Wendtner, C.M., 2013. Clinical features and virological analysis of a case of Middle East
942 respiratory syndrome coronavirus infection. *Lancet Infect. Dis.* 13, 745–751.
943 [https://doi.org/10.1016/S1473-3099\(13\)70154-3](https://doi.org/10.1016/S1473-3099(13)70154-3)

944 Du, W., Yu, J., Liu, X., Chen, H., Lin, L., Li, Q., 2020a. Persistence of SARS-CoV-2 virus RNA in
 945 feces: A case series of children. *J. Infect. Public Health* 13, 926-931.
 946 <https://doi.org/10.1016/j.jiph.2020.05.025>

947 Du, M., Cai, G., Chen, F., Christiani, D.C., Zhang, Z., Wang, M., 2020b. Multiomics evaluation of
 948 gastrointestinal and other clinical characteristics of Severe Acute Respiratory Syndrome
 949 Coronavirus 2 and Coronavirus Disease 2019. *Gastroenterology* 158, 2298-2301.
 950 <https://doi.org/10.1053/j.gastro.2020.03.045>

951 Dufour, A.P., Behymer, T.D., Cantú, R., Magnuson, M., Wymer, L.J., 2017. Ingestion of
 952 swimming pool water by recreational swimmers. *J. Water Health* 15, 429–437.
 953 <https://doi.org/10.2166/wh.2017.255>

954 ECDC, 2020. Disinfection of environments in healthcare and nonhealthcare settings potentially
 955 contaminated with SARS-CoV-2. European Centre for Disease Prevention and Control, Solna
 956 Sweden.

957 Ejtahed, H.S., Hasani-Ranjbar, S., Siadat, S.D., Larijani, B., 2020. The most important challenges
 958 ahead of microbiome pattern in the post era of the COVID-19 pandemic. *J. Diabetes Metab.*
 959 *Disord. in press.* <https://doi.org/10.1007/s40200-020-00579-0>

960 Esper, F., Ou, Z., Huang, Y.T., 2010. Human coronaviruses are uncommon in patients with
 961 gastrointestinal illness. *J. Clin. Virol.* 48, 131–133. <https://doi.org/10.1016/j.jcv.2010.03.007>

962 Fitzek, A., Sperhake, J., Edler, C., Schröder, A.S., Heinemann, A., Heinrich, F., Ron, A.,
 963 Mushumba, H., Lütgehetmann, M., Püschel, K., 2020. Evidence for systematic autopsies in
 964 COVID-19 positive deceased: Case report of the first German investigated COVID-19 death.
 965 *Rechtsmedizin* 30, 184–189. <https://doi.org/10.1007/s00194-020-00401-4>

966 Fletcher, S.M., Lewis-Fuller, E., Williams, H., Miller, Z., Scarlett, H.P., Cooper, C., Gordon-
 967 Johnson, K.A., Vickers, I., Shaw, K., Wellington, I., Thame, J., Pérez, E., Indar, L., 2013.
 968 Magnitude, distribution, and estimated level of underreporting of acute gastroenteritis in

969 Jamaica. J. Heal. Popul. Nutr. 31, 69-80. <https://doi.org/10.3329/jhpn.v31i4.2310>

970 Foladori, P., Cutrupi, F., Segata, N., Manara, S., Pinto, F., Malpei, F., Bruni, L., La Rosa, G., 2020.

971 SARS-CoV-2 from faeces to wastewater treatment: What do we know? A review. Sci. Total

972 Environ. 743, 140444. <https://doi.org/10.1016/j.scitotenv.2020.140444>

973 Franco-Paredes, C., Jankousky, K., Schultz, J., Bernfeld, J., Cullen, K., Quan, N.G., Kon, S., Hotez,

974 P., Henao-Martínez, A.F., Krsak, M., 2020. COVID-19 in jails and prisons: A neglected

975 infection in a marginalized population. PLoS Negl. Trop. Dis. 14, e0008409.

976 <https://doi.org/10.1371/journal.pntd.0008409>

977 Galbadage, T., Peterson, B.M., Gunasekera, R.S., 2020. Does COVID-19 spread through droplets

978 alone? Front. Public Heal. 8, 1–4. <https://doi.org/10.3389/fpubh.2020.00163>

979 Gaunt, E.R., Hardie, A., Claas, E.C.J., Simmonds, P., Templeton, K.E., 2010. Epidemiology and

980 clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43

981 detected over 3 years using a novel multiplex real-time PCR method. J. Clin. Microbiol. 48,

982 2940-2947. <https://doi.org/10.1128/JCM.00636-10>

983 Gleizes, O., Desselberger, U., Tatochenko, V., Rodrigo, C., Salman, N., Mezner, Z., Giaquinto, C.,

984 Grimprel, E., 2006. Nosocomial rotavirus infection in European countries: A review of the

985 epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr.

986 Infect. Dis. J. 25, 12–21. <https://doi.org/10.1097/01.inf.0000197563.03895.91>

987 Gong, K., Xu, Z., Cai, Z., Chen, Y., Wang, Z., 2020. Internet hospitals help prevent and control the

988 epidemic of COVID-19 in China: Multicenter user profiling study. J. Med. Internet Res. 22.

989 <https://doi.org/10.2196/18908>

990 Güemes-Villahoz, N., Burgos-Blasco, B., Arribi-Vilela, A., Arriola-Villalobos, P., Rico-Luna, C.

991 M., Cuiña-Sardiña, R., Delgado-Iribarren, A., García-Feijóo, J., 2020. Detecting SARS-CoV-

992 2 RNA in conjunctival secretions: Is it a valuable diagnostic method of COVID-19? J. Med.

993 Virol. *In press*. <https://doi.org/10.1002/jmv.26219>

994 Gurung, M., Li, Z.P., You, H., Rodrigues, R., Jump, D.B., Morgun, A., Shulzhenko, N., 2023. Role
 995 of gut microbiota in type 2 diabetes pathophysiology. *EBioMedicine* 51, UNSP102590.
 996 <https://doi.org/10.1016/j.ebiom.2019.11.051>

997 Guo, A.X., Cui, J.J., OuYang, Q.Y., He, L., Guo, C.X., Yin, J.Y., 2020b. The clinical
 998 characteristics and mortal causes analysis of COVID-19 death patients. *medRxiv*
 999 2020.04.12.20062380. <https://doi.org/10.1101/2020.04.12.20062380>

1000 Guo, Y.R., Cao, Q.D., Hong, Z.S., Tan, Y.Y., Chen, S.D., Jin, H.J., Tan, K. Sen, Wang, D.Y., Yan,
 1001 Y., 2020a. The origin, transmission and clinical therapies on coronavirus disease 2019
 1002 (COVID-19) outbreak: An update on the status. *Mil. Med. Res.* 7, 1–10.
 1003 <https://doi.org/10.1186/s40779-020-00240-0>

1004 Gupta, S., Parker, J., Smits, S., Underwood, J., Dolwani, S., 2020. Persistent viral shedding of
 1005 SARS-CoV-2 in faeces - a rapid review. *Colorectal Disease* 22, 611-620.
 1006 <https://doi.org/10.1111/codi.15138>

1007 Hall, A.J., Lopman, B.A., Payne, D.C., Patel, M.M., Gastañaduy, P.A., Vinjé, J., Parashar, U.D.,
 1008 2013. Norovirus disease in the united states. *Emerg. Infect. Dis.* 19, 1198–1205.
 1009 <https://doi.org/10.3201/eid1908.130465>

1010 Han, M.S., Seong, M.W., Heo, E.Y., Park, J.H., Kim, N., Shin, S., Cho, S.I., Park, S.S., Choi, E.H.,
 1011 2020. Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-
 1012 2. *Clin. Infect. Dis.* 1–4. <https://doi.org/10.1093/cid/ciaa447>

1013 Harcourt, J., Tamin, A., Lu, X., Kamili, S., Sakthivel, S.K., Murray, J., Queen, K., Tao, Y., Paden,
 1014 C.R., Zhang, J., Li, Y., Uehara, A., Wang, H., Goldsmith, C., Bullock, H.A., Wang, L.,
 1015 Whitaker, B., Lynch, B., Gautam, R., Schindewolf, C., Lokugamage, K.G., Scharton, D.,
 1016 Plante, J.A., Mirchandani, D., Widen, S.G., Narayanan, K., Makino, S., Ksiazek, T.G., Plante,
 1017 K.S., Weaver, S.C., Lindstrom, S., Tong, S., Menachery, V.D., Thornburg, N.J., 2020. Severe
 1018 Acute Respiratory Syndrome Coronavirus 2 from patient with coronavirus disease, United

1019 States. *Emerg. Infect Dis.* 26, 1266-1273. <https://doi.org/10.3201/eid2606.200516>

1020 Haug, T. T., Mykletun, A., Dahl, A.A., 2002a. The prevalence of nausea in the community:
 1021 Psychological, social and somatic factors. *Gen. Hosp. Psychiatry* 24, 81–86.
 1022 [https://doi.org/10.1016/S0163-8343\(01\)00184-0](https://doi.org/10.1016/S0163-8343(01)00184-0)

1023 Haug, T. Tangen., Mykletun, A., Dahl, A.A., 2002b. Are anxiety and depression related to
 1024 gastrointestinal symptoms in the general population? *Scand. J. Gastroenterol.* 37, 294–298.
 1025 <https://doi.org/10.1080/003655202317284192>

1026 He, J., Tao, H., Yan, Y., Huang, S.Y., Xiao, Y., 2020b. Molecular mechanism of evolution and
 1027 human infection with SARS-CoV-2. *Viruses* 12, 428. <https://doi.org/10.3390/v12040428>

1028 He, X., Lau, E.H.Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y.C., Wong, J.Y., Guan, Y., Tan,
 1029 X., Mo, X., Chen, Y., Liao, B., Chen, W., Hu, F., Zhang, Q., Zhong, M., Wu, Y., Zhao, L.,
 1030 Zhang, F., Cowling, B.J., Li, F., Leung, G.M., 2020a. Temporal dynamics in viral shedding
 1031 and transmissibility of COVID-19. *Nat. Med.* 26, 672–675. [https://doi.org/10.1038/s41591-](https://doi.org/10.1038/s41591-020-0869-5)
 1032 [020-0869-5](https://doi.org/10.1038/s41591-020-0869-5)

1033 Hirano, N., Fujiwara, K., Matumoto, M., 1976. Mouse hepatitis virus (MHV-2). Plaque assay and
 1034 propagation in mouse cell line DBT cells. *Jpn. J. Microbiol.* 20, 219-225.

1035 Hirose, R., Nakaya, T., Naito, Y., Daidoji, T., Watanabe, Y., Yasuda, H., Konishi, H., Itoh, Y.,
 1036 2017. Mechanism of human influenza virus RNA persistence and virion survival in feces:
 1037 Mucus protects virions from acid and digestive juices. *J. Infect. Dis.* 216, 105–109.
 1038 <https://doi.org/10.1093/infdis/jix224>

1039 Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens,
 1040 T.S., Herrler, G., Wu, N.H., Nitsche, A., Müller, M.A., Drosten, C., Pöhlmann, S., 2020.
 1041 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically
 1042 proven protease inhibitor. *Cell* 181, 271-280.e8. <https://doi.org/10.1016/j.cell.2020.02.052>

1043 Honarmand Ebrahimi, K., 2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by

upper respiratory tract bacteria may prevent severe viral infection. *FEBS Lett.* 594, 1651–1660. <https://doi.org/10.1002/1873-3468.13845>

Hosoda, T., Sakamoto, M., Shimizu, H., Okabe, N., 2020. SARS-CoV-2 enterocolitis with persisting to excrete the virus for about two weeks after recovering from diarrhea: A case report. *Infect. Control Hosp. Epidemiol.* 753–754. <https://doi.org/10.1017/ice.2020.87>

Hua, C.Z., Miao, Z.P., Zheng, J.S., Huang, Q., Sun, Q.F., Lu, H.P., Su, F.F., Wang, W.H., Huang, L.P., Chen, D.Q., Xu, Z. W., Ji, L.D., Zhang, H.P., Yang, X.W., Li, M.H., Mao, Y.Y., Ying, M.Z., Ye, S., Shu, Q., Chen, E.F., Fu, J.F., 2020. Epidemiological features and viral shedding in children with SARS-CoV-2 infection. *J. Med. Virol.* *In press*. <https://doi.org/10.1002/jmv.26180>

Huang, J., Mao, T., Li, S., Wu, L., Xu, X., Li, H., Xu, C., Su, F., Dai, J., Shi, J., Cai, J., Huang, C., Lin, X., Chen, D., Lin, X., Sun, B., Tang, S., 2020b. Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study. *medRxiv* 2020.04.22.20071258. <https://doi.org/10.1101/2020.04.22.20071258>

Huang, Y., Chen, S., Yang, Z., Guan, W., Liu, D., Lin, Z., Zhang, Y., Xu, Z., Liu, X., Li, Y., 2020a. SARS-CoV-2 viral load in clinical samples from critically ill patients. *Am. J. Respir. Crit. Care Med.* 201, 1435–1438. <https://doi.org/10.1164/rccm.202003-0572LE>

Hung, I.F.N., Lau, S.K.P., Woo, P.C.Y., Yuen, K.Y., 2009. Viral loads in clinical specimens and SARS manifestations. *Hong Kong Med. J.* 15, 20–22. <https://doi.org/10.3201/eid1009.040058>

Iorgulescu, G., 2009. Saliva between normal and pathological. Important factors in determining systemic and oral health. *J. Med. Life* 2, 303–307.

Iwasaki, A., Grubaugh, N.D., 2020. Why does Japan have so few cases of COVID- 19? *EMBO Mol. Med.* 12, 10–12. <https://doi.org/10.15252/emmm.202012481>

Jiang, X., Luo, M., Zou, Z., Wang, X., Chen, C., Qiu, J., 2020. Asymptomatic SARS-CoV-2 infected case with viral detection positive in stool but negative in nasopharyngeal samples

1069 lasts for 42 days. *J. Med. Virol. In press*. <https://doi.org/10.1002/jmv.25941>

1070 Jung, K., Wang, Q., Scheuer, K.A., Lu, Z., Zhang, Y., Saif, L.J., 2014. Pathology of US porcine
 1071 epidemic diarrhea virus strain PC21A in gnotobiotic pigs. *Emerg. Infect. Dis.* 20, 662-665.
 1072 <https://doi.org/10.3201/eid2004.131685>

1073 Jung, Y.J., Park, G.-S., Moon, J.H., Ku, K., Beak, S.-H., Kim, Seil, Park, E.C., Park, D., Lee, J.-H.,
 1074 Byeon, C.W., Lee, J.J., Maeng, J., Kim, S.J., Kim, Seung Il, Kim, B.-T., Lee, M.J., Kim, H.G.,
 1075 2020. Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-
 1076 CoV-2. *BioRxiv* 2020.02.25.964775. <https://doi.org/10.1101/2020.02.25.964775>

1077 Kalantar-Zadeh, Kourosh, Ward, S.A., Kalantar-Zadeh, Kamyar, El-Omar, E.M., 2020.
 1078 Considering the effects of microbiome and diet on SARS-CoV-2 infection: Nanotechnology
 1079 roles. *ACS Nano* 14, 5179–5182. <https://doi.org/10.1021/acsnano.0c03402>

1080 Kampf, G., Todt, D., Pfaender, S., Steinmann, E., 2020. Persistence of coronaviruses on inanimate
 1081 surfaces and their inactivation with biocidal agents. *J. Hosp. Infect.* 104, 246–251.
 1082 <https://doi.org/10.1016/j.jhin.2020.01.022>

1083 Kanwar, A., Selvaraju, S., Esper, F., 2017. Human coronavirus-HKU1 infection among adults in
 1084 Cleveland, Ohio. *Open Forum Infect. Dis.* 4, 1–6. <https://doi.org/10.1093/ofid/ofx052>

1085 Kashi, A.H., Fallah-karkan, M., Amini, E., Vaezjalali, M., 2020. The presence of COVID-19 in
 1086 urine: A systematic review and meta-analysis of the literature. *medRxiv* 2020.05.15.20094920.
 1087 <https://doi.org/10.1101/2020.05.15.20094920>

1088 Keller, V.D.J., Williams, R.J., Lofthouse, C., Johnson, A.C., 2014. Worldwide estimation of river
 1089 concentrations of any chemical originating from sewage-treatment plants using dilution
 1090 factors. *Environ. Toxicol. Chem.* 33, 447–452. <https://doi.org/10.1002/etc.2441>

1091 Kheyami, A.M., Nakagomi, T., Nakagomi, O., Getty, B., Hart, C.A., Cunliffe, N.A., 2010.
 1092 Detection of coronaviruses in children with acute gastroenteritis in Maddina, Saudi Arabia.
 1093 *Ann. Trop. Paediatr.* 30, 45–50. <https://doi.org/10.1179/146532810X12637745451997>

1094 Kim, D., Quinn, J., Pinsky, B., Shah, N.H., Brown, I., 2020. Rates of co-infection between SARS-
1095 CoV-2 and other respiratory pathogens. *J. Am. Med. Assoc.* 323, 2085–2086.
1096 <https://doi.org/10.1001/jama.2020.6266>

1097 Kirby, A.E., Streby, A., Moe, C.L., 2016. Vomiting as a symptom and transmission risk in
1098 norovirus illness: Evidence from human challenge studies. *PLoS One* 11, 1–10.
1099 <https://doi.org/10.1371/journal.pone.0143759>

1100 Kotloff, K.L., Nasrin, D., Blackwelder, W.C., Wu, Y., Farag, T., Panchalingham, S., Sow, S.O.,
1101 Sur, D., Zaidi, A.K.M., Faruque, A.S.G., Saha, D., Alonso, P.L., Tamboura, B., Sanogo, D.,
1102 Onwuchekwa, U., Manna, B., Ramamurthy, T., Kanungo, S., Ahmed, S., Qureshi, S., Quadri,
1103 F., Hossain, A., Das, S.K., Antonio, M., Hossain, M.J., Mandomando, I., Acácio, S., Biswas,
1104 K., Tennant, S.M., Verweij, J.J., Sommerfelt, H., Nataro, J.P., Robins-Browne, R.M., Levine,
1105 M.M., 2019. The incidence, aetiology, and adverse clinical consequences of less severe
1106 diarrhoeal episodes among infants and children residing in low-income and middle-income
1107 countries: a 12-month case-control study as a follow-on to the Global Enteric Multicenter
1108 Study (GEMS). *Lancet Glob. Heal.* 7, e568-e584. [https://doi.org/10.1016/S2214-](https://doi.org/10.1016/S2214-109X(19)30076-2)
1109 [109X\(19\)30076-2](https://doi.org/10.1016/S2214-109X(19)30076-2)

1110 Koyama, T., Weeraratne, D., Snowden, J.L., Parida, L., 2020. Emergence of drift variants that may
1111 affect COVID-19 vaccine development and antibody treatment. *Pathogens* 9, 324.
1112 <https://doi.org/10.3390/pathogens9050324>.

1113 Kwan, A.C., Chau, T., Tong, W., Tsang, O.T., Tso, E.Y., Chiu, M., Yu, W., Lai, T.S., 2005. Severe
1114 acute respiratory syndrome-related diarrhea. *J. Gastroenterol. Hepatol.* 20, 606–610.
1115 <https://doi.org/10.1111/j.1400-1746.2005.03775.x>

1116 La Scola, B., Le Bideau, M., Andreani, J., Hoang, V.T., Grimaldier, C., Colson, P., Gautret, P.,
1117 Raoult, D., 2020. Viral RNA load as determined by cell culture as a management tool for
1118 discharge of SARS-CoV-2 patients from infectious disease wards. *Eur. J. Clin. Microbiol.*

1119 Infect. Dis. 39, 1059–1061. <https://doi.org/10.1007/s10096-020-03913-9>

1120 Lai, C.C., Wang, Y.H., Wu, C.Y., Hung, C.H., Jiang, D.D.S., Wu, F.T., 2013. A norovirus outbreak
 1121 in a nursing home: Norovirus shedding time associated with age. *J. Clin. Virol.* 56, 96–101.
 1122 <https://doi.org/10.1016/j.jcv.2012.10.011>

1123 Lai, M.Y.Y., Cheng, P.K.C., Lim, W.W.L., 2005. Survival of Severe Acute Respiratory Syndrome
 1124 coronavirus. *Clin. Infect. Dis.* 41, e67–e71. <https://doi.org/10.1086/433186>

1125 Lam, J.C.M., Moshi, G.B., Ang, S.H., Chew, H.M., Ng, Q.H., Madjokie, A., Logeswary, M., 2020.
 1126 Management of COVID-19 related paediatric blood samples in a clinical haematology
 1127 laboratory. *Br. J. Haematol.* 189, 848–851. <https://doi.org/10.1111/bjh.16721>

1128 Lamers, M. M., Beumer, J., van der Vaart, J., Knoops, K., Puschhof, J., Breugem, T. I., Ravelli, R.,
 1129 Paul van Schayck, J., Mykytyn, A. Z., Duimel, H. Q., van Donselaar, E., Riesebosch, S.,
 1130 Kuijpers, H., Schipper, D., van de Wetering, W. J., de Graaf, M., Koopmans, M., Cuppen, E.,
 1131 Peters, P. J., Haagmans, B. L., Clevers, H., 2020. SARS-CoV-2 productively infects human
 1132 gut enterocytes. *Science* 369, 50–54. <https://doi.org/10.1126/science.abc1669>

1133 Lee, N., Chan, M.C.W., Wong, B., Choi, K.W., Sin, W., Lui, G., Chan, P.K.S., Lai, R.W.M.,
 1134 Cockram, C.S., Sung, J.J.Y., Leung, W.K., 2007. Fecal viral concentration and diarrhea in
 1135 norovirus gastroenteritis. *Emerg. Infect. Dis.* 13, 1399–1401.
 1136 <https://doi.org/10.3201/eid1309.061535>

1137 Li, C.C., Wang, L., Eng, H.L., You, H.L., Chang, L.S., Tang, K.S., Lin, Y.J., Kuo, H.C., Lee, I.K.,
 1138 Liu, J.W., Huang, E.Y., Yang, K.D., 2010b. Correlation of pandemic (H1N1) 2009 viral load
 1139 with disease severity and prolonged viral shedding in children. *Emerg. Infect. Dis.* 16, 1265–
 1140 1272. <https://doi.org/10.3201/eid1608.091918>

1141 Li, D., Jin, M., Bao, P., Zhao, W., Zhang, S., 2020e. Clinical characteristics and results of semen
 1142 tests among men with coronavirus disease 2019. *JAMA Netw. open* 3, e208292.
 1143 <https://doi.org/10.1001/jamanetworkopen.2020.8292>

1144 Li, D., Zhao, M.Y., Tan, T.H.M., 2021. What makes a foodborne virus: comparing coronaviruses
 1145 with human noroviruses. *Curr. Opin. Food Sci.* 42, 1–7.
 1146 <https://doi.org/10.1016/j.cofs.2020.04.011>
 1147 Li, H., Liu, L., Zhang, D., Xu, J., Dai, H., Tang, N., Su, X., Cao, B., 2020d. SARS-CoV-2 and viral
 1148 sepsis: observations and hypotheses. *Lancet* 395, 1517–1520. <https://doi.org/10.1016/S0140->
 1149 [6736\(20\)30920-X](https://doi.org/10.1016/S0140-6736(20)30920-X)
 1150 Li, M.Y., Li, L., Zhang, Y., Wang, X.S., 2020c. Expression of the SARS-CoV-2 cell receptor gene
 1151 ACE2 in a wide variety of human tissues. *Infect. Dis. Poverty* 9, 1–7.
 1152 <https://doi.org/10.1186/s40249-020-00662-x>
 1153 Li, R.-L., Chu, S.-G., Luo, Y., Huang, Z.-H., Hao, Y., Fan, C.-H., 2020a. Atypical presentation of
 1154 SARS-CoV-2 infection: A case report. *World J. Clin. Cases* 8, 1265–1270.
 1155 <https://doi.org/10.12998/wjcc.v8.i7.1265>
 1156 Li, Y.Y., Wang, J.X., Chen, X., 2020f. Can a toilet promote virus transmission? From a fluid
 1157 dynamics perspective. *Phys. Fluids* 32, 065107. <https://doi.org/10.1063/5.0013318>
 1158 Lin, L., Jiang, X., Zhang, Zhenling, Huang, S., Zhang, Zhenyi, Fang, Z., Gu, Z., Gao, L., Shi, H.,
 1159 Mai, L., Liu, Y., Lin, X., Lai, R., Yan, Z., Li, X., Shan, H., 2020. Gastrointestinal symptoms
 1160 of 95 cases with SARS-CoV-2 infection. *Gut* 69, 997–1001. <https://doi.org/10.1136/gutjnl->
 1161 [2020-321013](https://doi.org/10.1136/gutjnl-2020-321013)
 1162 Ling, Y., Xu, S.B., Lin, Y.X., Tian, D., Zhu, Z.Q., Dai, F.H., Wu, F., Song, Z.G., Huang, W., Chen,
 1163 J., Hu, B.J., Wang, S., Mao, E.Q., Zhu, L., Zhang, W.H., Lu, H.Z., 2020. Persistence and
 1164 clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chin. Med. J.*
 1165 *133*, 1039–1043. <https://doi.org/10.1097/CM9.0000000000000774>
 1166 Liu, J., Xiao, Y., Shen, Y., Shi, C., Chen, Y., Shi, P., Gao, Y., Wang, Y., Lu, B., 2020c. Detection
 1167 of SARS-CoV-2 by RT-PCR in anal from patients who have recovered from coronavirus
 1168 disease 2019. *J. Med. Virol.* 2019–2021. <https://doi.org/10.1002/jmv.25875>

1169 Liu, S., Liu, Ying, Liu, Yong, 2020a. Somatic symptoms and concern regarding COVID-19 among
1170 Chinese college and primary school students: A cross-sectional survey. *Psychiatry Res.* 289,
1171 113070. <https://doi.org/10.1016/j.psychres.2020.113070>

1172 Liu, Y., Yan, L.M., Wan, L., Xiang, T.X., Le, A., Liu, J.M., Peiris, M., Poon, L.L.M., Zhang, W.,
1173 2020. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect. Dis.* 20, 656–657.
1174 [https://doi.org/10.1016/S1473-3099\(20\)30232-2](https://doi.org/10.1016/S1473-3099(20)30232-2)

1175 Liu, Y.Y., Ning, Z., Chen, Y., Guo, M., Liu, Y.Y., Gali, N.K., Sun, L., Duan, Y., Cai, J.,
1176 Westerdahl, D., Liu, X., Ho, K., Kan, H., Fu, Q., Lan, K., 2020d. Aerodynamic characteristics
1177 and RNA concentration of SARS-CoV-2 aerosol in Wuhan hospitals during COVID-19
1178 outbreak. *bioRxiv* 86, 2020.03.08.982637. <https://doi.org/10.1101/2020.03.08.982637>

1179 Lo, I.L., Lio, C.F., Cheong, H.H., Lei, C.I., Cheong, T.H., Zhong, X., Tian, Y., Sin, N.N., 2020.
1180 Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of
1181 10 patients with COVID-19 in Macau. *Int. J. Biol. Sci.* 16, 1698–1707.
1182 <https://doi.org/10.7150/ijbs.45357>

1183 Lotfinejad, N., Peters, A., Pittet, D., 2020. Hand hygiene and the novel coronavirus pandemic: The
1184 role of healthcare workers. *J. Hosp. Infect. In press*. <https://doi.org/10.1016/j.jhin.2020.03.017>

1185 Lowe, C.F., Matic, N., Ritchie, G., Lawson, T., Stefanovic, A., Champagne, S., Leung, V.,
1186 Romney, M.G., 2020. Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal
1187 swabs using three commercial molecular assays. *J. Clin. Virol.* 128, 104387.
1188 <https://doi.org/10.1016/j.jcv.2020.104387>

1189 Lu, J., du Plessis, L., Liu, Z., Hill, V., Kang, M., Lin, H., Sun, J., François, S., Kraemer, M.U.G.,
1190 Faria, N.R., McCrone, J.T., Peng, J., Xiong, Q., Yuan, R., Zeng, L., Zhou, P., Liang, C., Yi,
1191 L., Liu, J., Xiao, J., Hu, J., Liu, T., Ma, W., Li, W., Su, J., Zheng, H., Peng, B., Fang, S., Su,
1192 W., Li, K., Sun, R., Bai, R., Tang, X., Liang, M., Quick, J., Song, T., Rambaut, A., Loman, N.,
1193 Raghwani, J., Pybus, O.G., Ke, C., 2020. Genomic epidemiology of SARS-CoV-2 in

Guangdong Province, China. *Cell* 181, 997–1003. <https://doi.org/10.1016/j.cell.2020.04.023>

Lytle, C.D., Sagripanti, J.L., 2005. Predicted inactivation of viruses of relevance to biodefense by solar radiation. *J. Virol.* 79, 14244–14252. <https://doi.org/10.1128/JVI.79.22.14244-14252.2005>

Ma, X., Su, L., Zhang, Y., Zhang, X., Gai, Z., Zhang, Z., 2020. Do children need a longer time to shed SARS-CoV-2 in stool than adults? *J. Microbiol. Immunol. Infect.* 53, 373–376. <https://doi.org/10.1016/j.jmii.2020.03.010>

Makison Booth, C., 2014. Vomiting Larry: a simulated vomiting system for assessing environmental contamination from projectile vomiting related to norovirus infection. *J. Infect. Prev.* 15, 176–180. <https://doi.org/10.1177/1757177414545390>

Makison Booth, C., Frost, G., 2019. Potential distribution of viable norovirus after simulated vomiting. *J. Hosp. Infect.* 102, 304–310. <https://doi.org/10.1016/j.jhin.2019.02.010>

Matsuyama, S., Nao, N., Shirato, K., Kawase, M., Saito, S., Takayama, I., Nagata, N., Sekizuka, T., Katoh, H., Kato, F., Sakata, M., Tahara, M., Kutsuna, S., Ohmagari, N., Kuroda, M., Suzuki, T., Kageyama, T., Takeda, M., 2020. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc. Natl. Acad. Sci. U.S.A.* 117, 7001–7003. <https://doi.org/10.1073/pnas.2002589117>

McKinney, K.R., Gong, Y.Y., Lewis, T.G., 2006. Environmental transmission of SARS at Amoy Gardens. *J. Environ. Health* 68, 26–30.

Mesoraca, A., Margiotti, K., Viola, A., Cima, A., Sparacino, D., Giorlandino, C., 2020. Evaluation of SARS-CoV-2 viral RNA in fecal samples. *Virol. J.* 17, 86. <https://doi.org/10.1186/s12985-020-01359-1>

Minodier, L., Masse, S., Capai, L., Blanchon, T., Ceccaldi, P.E., van der Werf, S., Hanslik, T., Charrel, R., Falchi, A., 2017. Clinical and virological factors associated with gastrointestinal symptoms in patients with acute respiratory infection: A two-year prospective study in general

1219 practice medicine. BMC Infect. Dis. 17, 1–11. <https://doi.org/10.1186/s12879-017-2823-9>

1220 Mönkemüller, K., Fry, L., Rickes, S., 2020. Covid-19, Coronavirus, SARS-CoV-2 and the small
 1221 bowel. Rev. Esp. Enferm. Dig. 112, 383–388. <https://doi.org/10.17235/reed.2020.7137/2020>

1222 NCIC-AMS, 2020. Period of infectivity to inform strategies for de-isolation for COVID-19
 1223 patients: Position statement. National Centre for Infectious Diseases and the Chapter of
 1224 Infectious Disease Physicians, Academy of Medicine, Singapore.

1225 Ng, M.L., Tan, S.H., See, E.E., Ooi, E.E., Ling, A.E., 2003. Early events of SARS coronavirus
 1226 infection in vero cells. J. Med. Virol. 71, 323–331. <https://doi.org/10.1002/jmv.10499>

1227 NIS-PHE, 2020. Review of data on persistence of SARS-CoV-2 in the environment and potential
 1228 infection risk. Virology Cell for the Scientific Advisory Group for Emergencies (SAGE), UK
 1229 Government, London, UK.

1230 ONS, 2020. Coronavirus (COVID-19) Infection survey pilot: England, 24th July 2020. Office for
 1231 National Statistics, London, UK.

1232 Ogando, N., Dalebout, T., Zevenhoven-Dobbe, J.C., Limpens, R.W.A.L., van der Meer, Y., Caly,
 1233 L., Druce, J., de Vries, J., Kikkert, M., Barcena, M., Sidorov, I., Snijder, E.J., 2020. SARS-
 1234 coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and
 1235 cytopathology. J. Gen. Virol. *In press*. <https://doi.org/10.1099/jgv.0.001453>

1236 Ong, S.W.X., Tan, Y.K., Chia, P.Y., Lee, T.H., Ng, O.T., Wong, M.S.Y., Marimuthu, K., 2020.
 1237 Air, surface environmental, and personal protective equipment contamination by severe acute
 1238 respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. J. Am. Med.
 1239 Assoc. 323, 1610–1612. <https://doi.org/10.1001/jama.2020.3227>

1240 Oran, D.P., Topol, E.J., 2020. Prevalence of asymptomatic SARS-CoV-2 infection. Ann. Intern.
 1241 Med. M20-3012. <https://doi.org/10.7326/M20-3012>

1242 Pal, M., Berhanu, G., Desalegn, C., Kandi, V., 2020. Severe Acute Respiratory Syndrome
 1243 Coronavirus-2 (SARS-CoV-2): An update. Cureus 12, e7423.

1244 <https://doi.org/10.7759/cureus.7423>

1245 Pasalari, H., Ataei-Pirkooh, A., Aminikhah, M., Jafari, A.J., Farzadkia, M., 2019. Assessment of
 1246 airborne enteric viruses emitted from wastewater treatment plant: Atmospheric dispersion
 1247 model, quantitative microbial risk assessment, disease burden. *Environ. Poll.* 253, 464-473.
 1248 <https://doi.org/10.1016/j.envpol.2019.07.010>

1249 Pan, F., Xiao, X., Guo, J., Song, Y., Li, H., Patel, D.P., Spivak, A.M., Alukal, J.P., Zhang, X.,
 1250 Xiong, C., Li, P.S., Hotaling, J.M., 2020c. No evidence of SARS-CoV-2 in semen of males
 1251 recovering from COVID-19. *Fertil. Steril.* 113, 1135-1139.
 1252 <https://doi.org/10.1016/j.fertnstert.2020.04.024>

1253 Pan, L., Mu, M., Yang, P., Sun, Y., Wang, R., Yan, J., Li, P., Hu, B., Wang, J., Hu, C., Jin, Y., Niu,
 1254 X., Ping, R., Du, Y., Li, T., Xu, G., Hu, Q., Tu, L., 2020d. Clinical characteristics of COVID-
 1255 19 patients with digestive symptoms in Hubei, China: A descriptive, cross-sectional,
 1256 multicenter study. *Am. J. Gastroenterol.* 115, 766–773.
 1257 <https://doi.org/10.14309/ajg.0000000000000620>

1258 Pan, Y., Long, L., Zhang, D., Yuan, T., Cui, S., Yang, P., Wang, Q., Ren, S., 2020a. Potential false-
 1259 negative nucleic acid testing results for severe acute respiratory syndrome coronavirus 2 from
 1260 thermal inactivation of samples with low viral loads. *Clin. Chem.* 66, 794–801.
 1261 <https://doi.org/10.1093/clinchem/hvaa091>

1262 Pan, Y., Zhang, D., Yang, P., Poon, L.L.M., Wang, Q., 2020b. Viral load of SARS-CoV-2 in
 1263 clinical samples. *Lancet Infect. Dis.* 20, 411–412. [https://doi.org/10.1016/S1473-](https://doi.org/10.1016/S1473-3099(20)30113-4)
 1264 [3099\(20\)30113-4](https://doi.org/10.1016/S1473-3099(20)30113-4)

1265 Paniri, A., Hosseini, M.M., Akhavan-Niaki, H., 2020. First comprehensive computational analysis
 1266 of functional consequences of TMPRSS2 SNPs in susceptibility to SARS-CoV-2 among
 1267 different populations. *J. Biomol. Struct. Dyn.* *In press.*
 1268 <https://doi.org/10.1080/07391102.2020.1767690>

1269 Panon, G., Tache, S., Labie, C., 1988. Respective stability of rotavirus and coronavirus in bovine
1270 milk. *Lait* 68, 49–64. <https://doi.org/10.1051/lait:198814>

1271 Paraskevis, D., Kostaki, E.G., Magiorkinis, G., Panayiotakopoulos, G., Sourvinos, G., Tsiodras, S.,
1272 2020. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the
1273 hypothesis of emergence as a result of a recent recombination event. *Infect. Genet. Evol.* 79,
1274 104212. <https://doi.org/10.1016/j.meegid.2020.104212>

1275 Parkkali, S., Joosten, R., Fanoy, E., Pijnacker, R., VAN Beek, J., Brandwagt, D., van Pelt, W.,
1276 2017. Outbreak of diarrhoea among participants of a triathlon and a duathlon on 12 July 2015
1277 in Utrecht, the Netherlands. *Epidemiol. Infect.* 145, 2176–2184.
1278 <https://doi.org/10.1017/S0950268817001017>

1279 Patel, A., 2020. Preventing COVID-19 amid public health and urban planning failures in slums of
1280 Indian cities. *World Medical & Health Policy* *in press*. <https://doi.org/10.1002/wmh3.351>

1281 Peccia, J., Zulli, A., Brackney, D.E., Grubaugh, N.D., Kaplan, E.H., Casanovas-Massana, A., Ko,
1282 A.I., Malik, A.A., Wang, D., Weinberger, D., Omer, S., 2020. SARS-CoV-2 RNA
1283 concentrations in primary municipal sewage sludge as a leading indicator of COVID-19
1284 outbreak dynamics. *medRxiv* <https://doi.org/10.1101/2020.05.19.20105999>

1285 Peckham, R., 2013. Economies of contagion: Financial crisis and pandemic. *Econ. Soc.* 42, 226–
1286 248. <https://doi.org/10.1080/03085147.2012.718626>

1287 Peiris, J.S.M., Chu, C.M., Cheng, V.C.C., Chan, K.S., Hung, I.F.N., Poon, L.L.M., Law, K.I., Tang,
1288 B.S.F., Hon, T.Y.W., Chan, C.S., Chan, K.H., Ng, J.S.C., Zheng, B.J., Ng, W.L., Lai, R.W.M.,
1289 Guan, Y., Yuen, K.Y., 2003. Clinical progression and viral load in a community outbreak of
1290 coronavirus-associated SARS pneumonia: A prospective study. *Lancet* 361, 1767–1772.
1291 [https://doi.org/10.1016/S0140-6736\(03\)13412-5](https://doi.org/10.1016/S0140-6736(03)13412-5)

1292 Peng, L., Liu, J., Xu, W., Luo, Q., Chen, D., Lei, Z., Huang, Z., Li, X., Deng, K., Lin, B., Gao, Z.,
1293 2020b. SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs

specimens. *J. Med. Virol. In press*. <https://doi.org/10.1002/jmv.25936>

Perlman, S., Netland, J., 2009. Coronaviruses post-SARS: Update on replication and pathogenesis. *Nat. Rev. Microbiol.* 7, 439–450. <https://doi.org/10.1038/nrmicro2147>

Petrosillo, N., Viceconte, G., Ergonul, O., Ippolito, G., Petersen, E., 2020. COVID-19, SARS and MERS: are they closely related? *Clin. Microbiol. Infect.* 20, 729-734. <https://doi.org/10.1016/j.cmi.2020.03.026>.

Pfefferle, S., Schöpf, J., Kögl, M., Friedel, C.C., Müller, M.A., Carbajo-Lozoya, J., Stellberger, T., von Dall’Armi, E., Herzog, P., Kallies, S., Niemeyer, D., Ditt, V., Kuri, T., Züst, R., Pumpor, K., Hilgenfeld, R., Schwarz, F., Zimmer, R., Steffen, I., Weber, F., Thiel, V., Herrler, G., Thiel, H.J., Schwegmann-Weßels, C., Pöhlmann, S., Haas, J., Drosten, C., von Brunn, A., 2011. The SARS-Coronavirus-host interactome: Identification of cyclophilins as target for pan-Coronavirus inhibitors. *PLoS Pathog.* 7, e1002331. <https://doi.org/10.1371/journal.ppat.1002331>

Pfeiffer, J.K., 2010. Innate host barriers to viral trafficking and population diversity: lessons learned from poliovirus. *Adv. Virus Res.* 77, 85–118. <https://doi.org/10.1016/B978-0-12-385034-8.00004-1>

Pillonel, T., Scherz, V., Jatón, K., Greub, G., Bertelli, C., 2020. Letter to the editor: SARS-CoV-2 detection by real-time RT-PCR. *Euro Surveill.* 25, 1–2. <https://doi.org/10.2807/1560-7917.ES.2020.25.21.2000880>

Pinky, L., Dobrovolny, H.M., 2020. SARS-CoV-2 coinfections: Could influenza and the common cold be beneficial? *J. Med. Virol. In press*. <https://doi.org/10.1002/jmv.26098>

Piras, A., Rizzo, D., Uzzau, S., De Riu, G., Rubino, S., Bussu, F., 2020. Inappropriate nasopharyngeal sampling for SARS-CoV-2 detection is a relevant cause of false-negative reports. *Otolaryngol. Head. Neck Surg.* 194599820931793. <https://doi.org/10.1177/0194599820931793>

1319 Poole, D.N., Escudero, D.J., Gostin, L.O., Leblang, D., Talbot, E.A., 2020. Responding to the
1320 COVID-19 pandemic in complex humanitarian crises. *Int. J. Equity Health* 19, 1–2.
1321 <https://doi.org/10.1186/s12939-020-01162-y>

1322 Prabhu, V., Hsu, E., Lestin, S., Soltanianzadeh, Y., Hadi, S., 2020. Bradycardia, renal failure,
1323 atrioventricular nodal blockade, shock, and hyperkalemia (BRASH) syndrome as a
1324 presentation of coronavirus disease 2019. *Cureus* 12, e7816.
1325 <https://doi.org/10.7759/cureus.7816>

1326 Rabaan, A.A., Al-Ahmed, S.H., Haque, S., Sah, R., Tiwari, R., Malik, Y.S., Dhama, K., Yatoo,
1327 M.I., Bonilla-Aldana, D.K., Rodriguez-Morales, A.J., 2020. SARS-CoV-2, SARS-CoV, and
1328 MERS-COV: A comparative overview. *Infez. Med.* 28, 174–184.

1329 Rahman, A., Sarkar, A., 2019. Risk factors for fatal Middle East respiratory syndrome coronavirus
1330 infections in Saudi Arabia: Analysis of the WHO Line list, 2013–2018. *Am. J. Public Health*
1331 109, 1288–1293. <https://doi.org/10.2105/AJPH.2019.305186>

1332 Rahman, H., Carter, I., Basile, K., Donovan, L., Kumar, S., Tran, T., Ko, D., Alderson, S.,
1333 Sivaruban, T., Eden, J. S., Rockett, R., O'Sullivan, M. V., Sintchenko, V., Chen, S. C.,
1334 Maddocks, S., Dwyer, D. E., Kok, J., 2020. Interpret with caution: An evaluation of the
1335 commercial AusDiagnostics versus in-house developed assays for the detection of SARS-
1336 CoV-2 virus. *J. Clin. Vir.* 127, 104374. <https://doi.org/10.1016/j.jcv.2020.104374>

1337 Rajgor, D.D., Lee, M.H., Archuleta, S., Bagdasarian, N., Quek, S.C., 2020. The many estimates of
1338 the COVID-19 case fatality rate. *Lancet. Infect. Dis.* 3099, 30244.
1339 [https://doi.org/10.1016/S1473-3099\(20\)30244-9](https://doi.org/10.1016/S1473-3099(20)30244-9)

1340 Randazzo, W., Truchado, P., Cuevas-Ferrando, E., Simón, P., Allende, A., Sánchez, G., 2020.
1341 SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area.
1342 *Water Res.* 181, 115942. <https://doi.org/10.1016/j.watres.2020.115942>

1343 Razum, O., Penning, V., Mohsenpour, A., Bozorgmehr, K., 2020. Covid-19 in refugee shelters: The
1344 German public health service needs strengthening now. *Gesundheitswesen* 82, 392-396.
1345 <https://doi.org/10.1055/a-1154-5063>

1346 Ren, S.Y., Wang, W.B., Hao, Y.G., Zhang, H.R., Wang, Z.C., Chen, Y.L., Gao, R.D. 2020.
1347 Stability and infectivity of coronaviruses in inanimate environments. *World J. Clin. Cases* 8,
1348 1391-1399. <https://doi.org/10.12998/wjcc.v8.i8.1391>

1349 Rimoldi, S.G., Stefani, F., Gigantiello, A., Polesello, S., Comandatore, F., Mileto, D., Maresca, M.,
1350 Longobardi, C., Mancon, A., Romeri, F., Pagani, C., Moja, L., Gismondo, M.R., Salerno, F.,
1351 2020. Presence and vitality of SARS-CoV-2 virus in wastewaters and rivers. *medRxiv*.
1352 <https://doi.org/https://doi.org/10.1101/2020.05.01.20086009>

1353 Risku, M., Lappalainen, S., Räsänen, S., Vesikari, T., 2010. Detection of human coronaviruses in
1354 children with acute gastroenteritis. *J. Clin. Virol.* 48, 27–30.
1355 <https://doi.org/10.1016/j.jcv.2010.02.013>

1356 Riviere, G., Fellous, A., Franco, A., Bernay, B., Favrel, P., 2011. A crucial role in fertility for the
1357 oyster angiotensin-converting enzyme orthologue CgACE. *PLoS One* 6, e27833.
1358 <https://doi.org/10.1371/journal.pone.0027833>

1359 Rizzatti, G., Lopetuso, L.R., Gibiino, G., Binda, C., Gasbarrini, A., 2017. Proteobacteria: A
1360 common factor in human diseases. *BioMed Res. Int.* 2017, 9351507.
1361 <https://doi.org/10.1155/2017/9351507>.

1362 Robilotti, E., Deresinski, S., Pinsky, B.A., 2015. Norovirus. *Clin. Microbiol. Rev.* 28, 134–164.
1363 <https://doi.org/10.1128/CMR.00075-14>

1364 Rovida, F., Campanini, G., Piralla, A., Adzasehoun, K.M.G., Sarasini, A., Baldanti, F., 2013.
1365 Molecular detection of gastrointestinal viral infections in hospitalized patients. *Diagn.*
1366 *Microbiol. Infect. Dis.* 77, 231–235. <https://doi.org/10.1016/j.diagmicrobio.2013.07.020>

1367 Roy, S.K., Akramuzzaman, S.M., Akbar, M.S., 1991. Persistent diarrhea: total gut transit time and

1368 its relationship with nutrient absorption and clinical response. *J. Pediatr. Gastroenterol. Nutr.*
 1369 13, 409–14.

1370 Rudney, J.D., Ji, Z., Larson, C.J., 1995. The prediction of saliva swallowing frequency in humans
 1371 from estimates of salivary flow-rate and the volume of saliva swallowed. *Arch. Oral Biol.* 40,
 1372 507-512. [https://doi.org/10.1016/0003-9969\(95\)00004-9](https://doi.org/10.1016/0003-9969(95)00004-9)

1373 Russo, G.S., Eftim, S.E., Goldstone, A.E., Dufour, A.P., Nappier, S.P., Wade, T.J., 2020.
 1374 Evaluating health risks associated with exposure to ambient surface waters during
 1375 recreational activities: A systematic review and meta-analysis. *Water Res. In press.*
 1376 <https://doi.org/10.1016/j.watres.2020.115729>

1377 Sagripanti, J., Lytle, C.D., 2020. Estimated inactivation of coronaviruses by solar radiation with
 1378 special reference to COVID- 19. *Photochem. Photobiol. In press.*
 1379 <https://doi.org/10.1111/php.13293>

1380 Salve, P.S., Jungari, S., 2020. Sanitation workers at the frontline: work and vulnerability in
 1381 response to COVID-19. *Local Environ. In press.*
 1382 <https://doi.org/10.1080/13549839.2020.1792430>

1383 Sassi, H.P., Reynolds, K.A., Pepper, I.L., Gerba, C.P., 2018. Evaluation of hospital-grade
 1384 disinfectants on viral deposition on surfaces after toilet flushing. *Am. J. Infect. Control* 46,
 1385 507–511. <https://doi.org/10.1016/j.ajic.2017.11.005>

1386 Schets, F.M., Schijven, J.F., de Roda Husman, A.M., 2011. Exposure assessment for swimmers in
 1387 bathing waters and swimming pools. *Water Res.* 45, 2392–2400.
 1388 <https://doi.org/10.1016/j.watres.2011.01.025>

1389 Schneider, M., Ackermann, K., Stuart, M., Wex, C., Protzer, U., Schätzl, H.M., Gilch, S., 2012.
 1390 Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due
 1391 to proteasome-independent inhibition of M-calpain. *J. Virol.* 86, 10112–10122.
 1392 <https://doi.org/10.1128/jvi.01001-12>

1393 Schrader, C., Schielke, A., Ellerbroek, L., Johne, R., 2012. PCR inhibitors - occurrence, properties
 1394 and removal. *J. Appl. Microbiol.* 113, 1014–1026. <https://doi.org/10.1111/j.1365->
 1395 2672.2012.05384.x
 1396 Schwierzeck, V., König, J.C., Kühn, J., Mellmann, A., Correa-Martínez, C.L., Omran, H., Konrad,
 1397 M., Kaiser, T., Kampmeier, S., 2020. First reported nosocomial outbreak of severe acute
 1398 respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit. *Clin. Infect.*
 1399 *Dis.* 2, 1–21. <https://doi.org/10.1093/cid/ciaa491>
 1400 Seitz, S.R., Leon, J.S., Schwab, K.J., Lyon, G.M., Dowd, M., McDaniels, M., Abdulhafid, G.,
 1401 Fernandez, M.L., Lindesmith, L.C., Baric, R.S., Moe, C.L., 2011. Norovirus infectivity in
 1402 humans and persistence in water. *Appl. Environ. Microbiol.* 77, 6884–6888.
 1403 <https://doi.org/10.1128/AEM.05806-11>
 1404 Seong, M.-W., Lee, S.J., Cho, S.I., Ko, K., Kim, M.-N., Sung, H., Kim, J.-S., Ahn, J.S., Yu, B.S.,
 1405 Kim, T.S., Kim, E.C., Park, S.S., 2016. External quality assessment of MERS-CoV molecular
 1406 diagnostics during the 2015 Korean outbreak. *Ann. Lab. Med.* 36, 230.
 1407 <https://doi.org/10.3343/alm.2016.36.3.230>
 1408 Sethuraman, N., Jeremiah, S.S., Ryo, A., 2020. Interpreting diagnostic tests for SARS-CoV-2. *J.*
 1409 *Am. Med. Assoc.* 2019, 2019–2021. <https://doi.org/10.1001/jama.2020.8259>
 1410 Shen, Q., Guo, W., Guo, T., Li, J., He, W., Ni, S., Ouyang, X., Liu, J., Xie, Y., Tan, X., Zhou, Z.,
 1411 Peng, H., 2020. Novel coronavirus infection in children outside of Wuhan, China. *Pediatr.*
 1412 *Pulmonol.* 1–6. <https://doi.org/10.1002/ppul.24762>
 1413 Shevlin, M., Nolan, E., Owczarek, M., McBride, O., Murphy, J., Gibson Miller, J., Hartman, T.K.,
 1414 Levita, L., Mason, L., Martinez, A.P., McKay, R., Stocks, T.V.A., Bennett, K.M., Hyland, P.,
 1415 Bentall, R.P., 2020. COVID-19-related anxiety predicts somatic symptoms in the UK
 1416 population. *Br. J. Health Psychol.* *In press*. <https://doi.org/10.1111/bjhp.12430>
 1417 Shin, N.R., Whon, T.W., Bae, J.W., 2015. Proteobacteria: Microbial signature of dysbiosis in gut

1418 microbiota. *Trends Biotechnol.* 33, 496–503. <https://doi.org/10.1016/j.tibtech.2015.06.011>

1419 Siddharta, A., Pfaender, S., Vielle, N.J., Dijkman, R., Friesland, M., Becker, B., Yang, J.,

1420 Engelman, M., Todt, D., Windisch, M.P., Brill, F.H., Steinmann, Joerg, Steinmann, Jochen,

1421 Becker, S., Alves, M.P., Pietschmann, T., Eickmann, M., Thiel, V., Steinmann, E., 2017.

1422 Virucidal activity of world health organization-recommended formulations against enveloped

1423 viruses, including zika, ebola, and emerging coronaviruses. *J. Infect. Dis.* 215, 902–906.

1424 <https://doi.org/10.1093/infdis/jix046>

1425 Smither, S.J., Eastaugh, L.S., Findlay, J.S., Lever, M.S., 2020. Experimental aerosol survival of

1426 SARS-CoV-2 in artificial saliva and tissue culture media at medium and high humidity.

1427 *Emerg. Microbes Infect.* 9, 1415–1417. <https://doi.org/10.1080/22221751.2020.1777906>

1428 Sommer, M., Ferron, S., Cavill, S., House, S., 2015. Violence, gender and WASH: spurring action

1429 on a complex, under-documented and sensitive topic. *Environ. Urban.* 27, 105–116.

1430 <https://doi.org/10.1177/0956247814564528>

1431 Srinivasan, A., Klepper, C., Sunkara, A., Kang, G., Carr, J., Gu, Z., Leung, W., Hayden, R.T.,

1432 2015. Impact of adenoviral stool load on adenoviremia in pediatric hematopoietic stem cell

1433 transplant recipients. *Pediatr. Infect. Dis. J.* 34, 562–5.

1434 <https://doi.org/10.1097/INF.0000000000000678>

1435 Stein, R.A., 2011. Super-spreaders in infectious diseases. *Int. J. Infect. Dis.* 15, e510–e513.

1436 <https://doi.org/10.1016/j.ijid.2010.06.020>

1437 Stone, D.L., Harding, A.K., Hope, B.K., Slaughter-Mason, S., 2008. Exposure assessment and risk

1438 of gastrointestinal illness among surfers. *J. Toxicol. Environ. Heal. A* 71, 1603–1615.

1439 <https://doi.org/10.1080/15287390802414406>

1440 Su, L., Ma, X., Yu, H., Zhang, Zhaohua, Bian, P., Han, Y., Sun, J., Liu, Y., Yang, C., Geng, J.,

1441 Zhang, Zhongfa, Gai, Z., 2020a. The different clinical characteristics of corona virus disease

1442 cases between children and their families in China—the character of children with COVID-19.

1443 Emerg. Microbes Infect. 9, 707–713. <https://doi.org/10.1080/22221751.2020.1744483>

1444 Su, H., Yang, M., Wan, C., Yi, L.X., Tang, F., Zhu, H.Y., Yi, F., Yang, H.C., Fogo, A.B., Nie, X.,
 1445 Zhang, C., 2020. Renal histopathological analysis of 26 postmortem findings of patients with
 1446 COVID-19 in China. *Kidney Int.* 98, 219–227. <https://doi.org/10.1016/j.kint.2020.04.003>.

1447 Sun, C.B., Wang, Y.Y., Liu, G.H., Liu, Z., 2020b. Role of the eye in transmitting human
 1448 coronavirus: what we know and what we do not know. *Front. Public Heal.* 8, 1–7.
 1449 <https://doi.org/10.3389/fpubh.2020.00155>

1450 Sun, J., Zhu, A., Li, H., Zheng, K., Zhuang, Z., Chen, Z., Shi, Y., Zhang, Z., Chen, S.B., Liu, X.,
 1451 Dai, J., Li, X., Huang, S., Huang, X., Luo, L., Wen, L., Zhuo, J., Li, Y., Wang, Y., Zhang, L.,
 1452 Zhang, Y., Li, F., Feng, L., Chen, X., Zhong, N., Yang, Z., Huang, J., Zhao, J., Li, Y.M.,
 1453 2020a. Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient. *Emerg.*
 1454 *Microbes Infect.* 1751, 1–8. <https://doi.org/10.1080/22221751.2020.1760144>

1455 Taxonera, C., Sagastagoitia, I., Alba, C., Mañas, N., Olivares, D., Rey, E., 2020. 2019 Novel
 1456 coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. *Aliment.*
 1457 *Pharmacol. Ther.* 52, 276–283. <https://doi.org/10.1111/apt.15804>

1458 Thalanayar Muthukrishnan, P., Faillace, R., 2020. Compassionate use of others' immunity -
 1459 understanding gut microbiome in Covid-19. *Critical Care* 24, 358.
 1460 <https://doi.org/10.1155/2017/9351507>

1461 Tian, P., Engelbrektson, A.L., Jiang, X., Zhong, W., Mandrell, R.E., 2007. Norovirus recognizes
 1462 histo-blood group antigens on gastrointestinal cells of clams, mussels, and oysters: A possible
 1463 mechanism of bioaccumulation. *J. Food Prot.* 70, 2140–2147. [https://doi.org/10.4315/0362-](https://doi.org/10.4315/0362-028X-70.9.2140)
 1464 [028X-70.9.2140](https://doi.org/10.4315/0362-028X-70.9.2140)

1465 Tian, Y., Rong, L., Nian, W., He, Y., 2020. Review article: gastrointestinal features in COVID-19
 1466 and the possibility of faecal transmission. *Aliment. Pharmacol. Ther.* 51, 843–851.
 1467 <https://doi.org/10.1111/apt.15731>

1468 To, K.K.W., Chan, K.-H., Li, I.W.S., Tsang, T.-Y., Tse, H., Chan, J.F.W., Hung, I.F.N., Lai, S.-T.,
1469 Leung, C.-W., Kwan, Y.-W., Lau, Y.-L., Ng, T.-K., Cheng, V.C.C., Peiris, J.S.M., Yuen, K.-
1470 Y., 2010. Viral load in patients infected with pandemic H1N1 2009 influenza A virus. *J. Med.*
1471 *Virol.* 82, 1–7. <https://doi.org/10.1002/jmv.21664>

1472 To, K.K.W., Tsang, O.T.Y., Chik-Yan Yip, C., Chan, K.H., Wu, T.C., Chan, J.M.C., Leung, W.S.,
1473 Chik, T.S.H., Choi, C.Y.C., Kandamby, D.H., Lung, D.C., Tam, A.R., Poon, R.W.S., Fung,
1474 A.Y.F., Hung, I.F.N., Cheng, V.C.C., Chan, J.F.W., Yuen, K.Y., 2020a. Consistent detection
1475 of 2019 novel coronavirus in saliva. *Clin. Infect. Dis.* ciaa149.
1476 <https://doi.org/10.1093/cid/ciaa149>

1477 To, K.K.W., Tsang, O.T.Y., Leung, W.S., Tam, A.R., Wu, T.C., Lung, D.C., Yip, C.C.Y., Cai, J.P.,
1478 Chan, J.M.C., Chik, T.S.H., Lau, D.P.L., Choi, C.Y.C., Chen, L.L., Chan, W.M., Chan, K.H.,
1479 Ip, J.D., Ng, A.C.K., Poon, R.W.S., Luo, C.T., Cheng, V.C.C., Chan, J.F.W., Hung, I.F.N.,
1480 Chen, Z., Chen, H., Yuen, K.Y., 2020b. Temporal profiles of viral load in posterior
1481 oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-
1482 2: an observational cohort study. *Lancet Infect. Dis.* 20, 565–574.
1483 [https://doi.org/10.1016/S1473-3099\(20\)30196-1](https://doi.org/10.1016/S1473-3099(20)30196-1)

1484 Todd, E.C.D., 2017. Foodborne disease and food control in the Gulf States. *Food Control* 73, 341–
1485 366. <https://doi.org/10.1016/j.foodcont.2016.08.024>

1486 Truelove, S., Abraham, O., Altare, C., Lauer, S. A., Grantz, K.H., Azman, A.S., Spiegel, P., 2020.
1487 The potential impact of COVID-19 in refugee camps in Bangladesh and beyond: A modeling
1488 study. *PLoS Med.* 17, e1003144. <https://doi.org/10.1371/journal.pmed.1003144>

1489 Tsang, K.W., Ho, P.L., Ooi, G.C., Yee, W.K., Wang, T., Chan-Yeung, M., Lam, W.K., Seto, W.H.,
1490 Yam, L.Y., Cheung, T.M., Wong, P.C., Lam, B., Ip, M.S., Chan, J., Yuen, K.Y., Lai, K.N.,
1491 2003. A Cluster of cases of severe acute respiratory syndrome in Hong Kong. *N. Engl. J. Med.*
1492 348, 1977–1985. <https://doi.org/10.1056/NEJMoa030666>

1493 Tung-Thompson, G., Gentry-Shields, J., Fraser, A., Jaykus, L.A., 2014. Persistence of human
 1494 Norovirus RT-qPCR signals in simulated gastric fluid. *Food Environ. Virol.* 7, 32–40.
 1495 <https://doi.org/10.1007/s12560-014-9170-4>
 1496 UNICEF-WHO, 2019. Progress on household drinking water, sanitation and hygiene 2000–2017:
 1497 special focus on inequalities. UN Children's Fund, World Health Organization, New York,
 1498 USA.
 1499 van Doremalen, N., Bushmaker, T., Morris, D.H., Holbrook, M.G., Gamble, A., Williamson, B.N.,
 1500 Tamin, A., Harcourt, J.L., Thornburg, N.J., Gerber, S.I., Lloyd-Smith, J.O., de Wit, E.,
 1501 Munster, V.J., 2020. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-
 1502 CoV-1. *N. Engl. J. Med.* 382, 1564–1567. <https://doi.org/10.1056/NEJMc2004973>
 1503 van Kasteren, P.B., van der Veer, B., van den Brink, S., Wijsman, L., de Jonge, J., van den Brandt,
 1504 A., Molenkamp, R., Reusken, C.B.E.M., Meijer, A., 2020. Comparison of seven commercial
 1505 RT-PCR diagnostic kits for COVID-19. *J. Clin. Virol.* 128, 104412.
 1506 <https://doi.org/10.1016/j.jcv.2020.104412>
 1507 van Wesenbeeck, L., D’Haese, D., Tolboom, J., Meeuws, H., Dwyer, D.E., Holmes, M., Ison,
 1508 M.G., Katz, K., McGeer, A., Sadoff, J., Weverling, G.J., Stuyver, L., 2015. A downward trend
 1509 of the ratio of Influenza RNA copy number to infectious viral titer in hospitalized influenza A-
 1510 infected patients. *Open forum Infect. Dis.* 2, ofv166. <https://doi.org/10.1093/ofid/ofv166>
 1511 Vignuzzi, M., López, C.B., 2019. Defective viral genomes are key drivers of the virus–host
 1512 interaction. *Nat. Microbiol.* 4, 1075–1087. <https://doi.org/10.1038/s41564-019-0465-y>
 1513 Vuille-Dit-Bille, R.N., Liechty, K.W., Verrey, F., Guglielmetti, L.C., 2020. SARS-CoV-2 receptor
 1514 ACE2 gene expression in small intestine correlates with age. *Amino Acids* *In press*.
 1515 <https://doi.org/10.1007/s00726-020-02870-z>
 1516 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y.,
 1517 Zhao, Y., Li, Y., Wang, X., Peng, Z., 2020b. Clinical Characteristics of 138 hospitalized

1518 patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *J. Am. Med.*
 1519 *Assoc.* 323, 1061–1069. <https://doi.org/10.1001/jama.2020.1585>

1520 Wang, J., Feng, H., Zhang, S., Ni, Z., Ni, L., Chen, Y., Zhuo, L., Zhong, Z., Qu, T., 2020d. SARS-
 1521 CoV-2 RNA detection of hospital isolation wards hygiene monitoring during the Coronavirus
 1522 Disease 2019 outbreak in a Chinese hospital. *Int. J. Infect. Dis.* 94, 103–106.
 1523 <https://doi.org/10.1016/j.ijid.2020.04.024>

1524 Wang, M., Yan, M., Xu, H., Liang, W., Kan, B., Zheng, B., Chen, H., Zheng, H., Xu, Y., Zhang,
 1525 E., Wang, H., Ye, J., Li, G., Li, M., Cui, Z., Liu, Y.F., Guo, R.T., Liu, X.N., Zhan, L.H., Zhou,
 1526 D.H., Zhao, A., Hai, R., Yu, D., Guan, Y., Xu, J., 2005a. SARS-CoV infection in a restaurant
 1527 from palm civet. *Emerg. Infect. Dis.* 11, 1860–1865. <https://doi.org/10.3201/eid1112.041293>

1528 Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., Tan, W., 2020c. Detection of SARS-CoV-2 in
 1529 different types of clinical specimens. *J. Am. Med. Assoc.* 323, 1843–1844.
 1530 <https://doi.org/10.1001/jama.2020.3786>

1531 Wang, X. W., Li, J., Guo, T., Zhen, B., Kong, Q., Yi, B., Li, Z., Song, N., Jin, M., Xiao, W., Zhu,
 1532 X., Gu, C., Yin, J., Wei, W., Yao, W., Liu, C., Li, J., Ou, G., Wang, M., Fang, T., Wang, G.,
 1533 Qiu, Y., Wu, H., Chao, F., Li, J., 2005c. Concentration and detection of SARS coronavirus in
 1534 sewage from Xiao Tang Shan hospital and the 309th Hospital of the Chinese People's
 1535 Liberation Army. *Water Sci. Technol.* 52, 213–221. <https://doi.org/10.2166/wst.2005.0266>

1536 Wang, X.W., Li, J.S., Guo, T.K., Zhen, B., Kong, Q.X., Yi, B., Li, Z., Song, N., Jin, M., Wu, X.M.,
 1537 Xiao, W.J., Zhu, X.M., Gu, C.Q., Yin, J., Wei, W., Yao, W., Liu, C., Li, J.F., Ou, G.R., Wang,
 1538 M.N., Fang, T.Y., Wang, G.J., Qiu, Y.H., Wu, H.H., Chao, F.H., Li, J.W., 2005b. Excretion
 1539 and detection of SARS coronavirus and its nucleic acid from digestive system. *World J.*
 1540 *Gastroenterol.* 11, 4390–4395. <https://doi.org/10.3748/wjg.v11.i28.4390>

1541 Wang, Y., Kang, H., Liu, X., Tong, Z., 2020a. Asymptomatic cases with SARS-CoV-2 infection. *J.*
 1542 *Med. Virol. In press.* <https://doi.org/10.1002/jmv.25990>

1543 Watanabe, T., Bartrand, T.A., Weir, M.H., Omura, T., Haas, C.N., 2010. Development of a dose-
1544 response model for SARS coronavirus. *Risk Anal.* 30, 1129–1138.
1545 <https://doi.org/10.1111/j.1539-6924.2010.01427.x>

1546 Watkins, K., 2018. Emerging infectious diseases: A review. *Curr. Emerg. Hosp. Med. Rep.* 6, 86–
1547 93. <https://doi.org/10.1007/s40138-018-0162-9>

1548 Wei, W.E., Li, Z., Chiew, C.J., Yong, S.E., Toh, M.P., Lee, V.J., 2020. Presymptomatic
1549 Transmission of SARS-CoV-2-Singapore. *Morb. Mortal. Wkly. Rep.* 69, 411–415.
1550 <http://dx.doi.org/10.15585/mmwr.mm6914e1>

1551 WHO, 2020. Water, sanitation, hygiene and waste management for the COVID-19 virus: Interim
1552 guidance. Who Global, World Health Organisation, Geneva, Switzerland.
1553 <https://doi.org/10.1056/NEJMoa2001191.7>

1554 WHO, 2018. 2018 review of diseases prioritized under the Research and Development Blueprint.
1555 World Health Organisation, Geneva, Switzerland.

1556 Wigginton, K.R., Ye, Y., Ellenberg, R.M., 2015. Emerging investigators series: The source and fate
1557 of pandemic viruses in the urban water cycle. *Environ. Sci. Water Res. Technol.* 1, 735–746.
1558 <https://doi.org/10.1039/c5ew00125k>

1559 Willumsen, T., Øgaard, B., Hansen, B.F., Rølla, G., 2004. Effects from pretreatment of stannous
1560 fluoride versus sodium fluoride on enamel exposed to 0.1 M or 0.01 M hydrochloric acid. *Acta*
1561 *Odontol. Scand.* 62, 278–281. <https://doi.org/10.1080/00016350410000174>

1562 Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A., Niemeyer, D.,
1563 Jones, T.C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T., Brünink, S., Schneider, J.,
1564 Ehmann, R., Zwirgmaier, K., Drosten, C., Wendtner, C., 2020. Virological assessment of
1565 hospitalized patients with COVID-2019. *Nature* 581, 465-469. [https://doi.org/10.1038/s41586-](https://doi.org/10.1038/s41586-020-2196-x)
1566 [020-2196-x](https://doi.org/10.1038/s41586-020-2196-x)

1567 Woo, P.C.Y., Huang, Y., Lau, S.K.P., Yuen, K.Y., 2010. Coronavirus genomics and bioinformatics

analysis. *Viruses* 2, 1805–1820. <https://doi.org/10.3390/v2081803>

Wu, F., Xiao, A., Zhang, J., Gu, X., Lee, W.L., Kauffman, K., Hanage, W., Matus, M., Ghaeli, N., Endo, N., Duvallet, C., Moniz, K., Erickson, T., Chai, P., Thompson, J., Alm, E., 2020b. SARS-CoV-2 titers in wastewater are higher than expected from clinically confirmed cases. *mSystems* 5, e00614-20. <https://doi.org/10.1128/mSystems.00614-20>

Wu, Y., Guo, C., Tang, L., Hong, Z., Zhou, J., Dong, X., Yin, H., Xiao, Q., Tang, Y., Qu, X., Kuang, L., Fang, X., Mishra, N., Lu, J., Shan, H., Jiang, G., Huang, X., 2020. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *lancet. Gastroenterol. Hepatol.* 5, 434–435. [https://doi.org/10.1016/S2468-1253\(20\)30083-2](https://doi.org/10.1016/S2468-1253(20)30083-2)

Wu, Z., McGoogan, J.M., 2020. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China. *J. Am. Med. Assoc.* 323, 1239. <https://doi.org/10.1001/jama.2020.2648>

Wurtzer, S., Marechal, V., Mouchel, J.-M., Maday, Y., Teyssou, R., Richard, E., Almayrac, J.L., Moulin, L., 2020. Evaluation of lockdown impact on SARS-CoV-2 dynamics through viral genome quantification in Paris wastewaters. *medRxiv* 2020.04.12.20062679. <https://doi.org/10.1101/2020.04.12.20062679>

Wurtzer, S., Marechal, V., Mouchel, J., Moulin, L., 2020. Time course quantitative detection of SARS-CoV-2 in Parisian wastewaters correlates with COVID-19 confirmed cases. *medRxiv* 10–13. <https://doi.org/https://doi.org/10.1101/2020.04.12.20062679>

Xiao, F., Sun, J., Xu, Y., Li, F., Huang, X., Li, H., Zhao, Jingxian, Huang, J., Zhao, J., 2020a. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. *Emerg. Infect. Dis.* 26. <https://doi.org/10.3201/eid2608.200681>

Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X., Shan, H., 2020b. Evidence for gastrointestinal infection of SARS-CoV-2. *Gastroenterology* 158, 1831-1833.e3. <https://doi.org/10.1053/j.gastro.2020.02.055>

1593 Xie, G.C., Yu, J.M., Duan, Z.J., 2013. New strategy for virus discovery: Viruses identified in
1594 human feces in the last decade. *Sci. China Life Sci.* 56, 688–696.
1595 <https://doi.org/10.1007/s11427-013-4516-y>

1596 Xu, Y., Li, X., Zhu, B., Liang, H., Fang, C., Gong, Y., Guo, Q., Sun, X., Zhao, D., Shen, J., Zhang,
1597 H., Liu, H., Xia, H., Tang, J., Zhang, K., Gong, S., 2020. Characteristics of pediatric SARS-
1598 CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat. Med.* 26, 502–
1599 505. <https://doi.org/10.1038/s41591-020-0817-4>

1600 Yan, Y., Chang, L., Wang, L., 2020. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-
1601 CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. *Rev. Med. Virol.* 30,
1602 1–14. <https://doi.org/10.1002/rmv.2106>

1603 Yang, K.X., Li, L., Wang, Y.J., Xue, S., Han, Y.P., Liu, J.X., 2019. Airborne bacteria in a
1604 wastewater treatment plant: Emission characterization, source analysis and health risk
1605 assessment. *Water Res.* 149, 596-606. <https://doi.org/10.1016/j.watres.2018.11.027>

1606 Yang, F., Shi, S., Zhu, J., Shi, J., Dai, K., Chen, X., 2020. Clinical characteristics and outcomes of
1607 cancer patients with COVID-19. *J. Med. Virol.* <https://doi.org/10.1002/jmv.25972>

1608 Yezli, S., Otter, J.A., 2011. Minimum infective dose of the major human respiratory and enteric
1609 viruses transmitted through food and the environment. *Food Environ. Virol.* 3, 1–30.
1610 <https://doi.org/10.1007/s12560-011-9056-7>

1611 Yoon, J.G., Yoon, J., Song, J.Y., Yoon, S.Y., Lim, C.S., Seong, H., Noh, J.Y., Cheong, H.J., Kim,
1612 W.J., 2020. Clinical significance of a high SARS-CoV-2 viral load in the saliva. *J. Korean*
1613 *Med. Sci.* 35, e195. <https://doi.org/10.3346/jkms.2020.35.e195>

1614 Yoshimoto, F.K., 2020. The proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS
1615 CoV-2 or n-COV19), the cause of COVID-19. *Protein J.* 39, 198–216.
1616 <https://doi.org/10.1007/s10930-020-09901-4>

1617 Young, B.E., Ong, S.W.X., Kalimuddin, S., Low, J.G., Tan, S.Y., Loh, J., Ng, O.T., Marimuthu,

1618 K., Ang, L.W., Mak, T.M., Lau, S.K., Anderson, D.E., Chan, K.S., Tan, T.Y., Ng, T.Y., Cui,
 1619 L., Said, Z., Kurupatham, L., Chen, M.I.C., Chan, M., Vasoo, S., Wang, L.F., Tan, B.H., Lin,
 1620 R.T.P., Lee, V.J.M., Leo, Y.S., Lye, D.C., 2020. Epidemiologic features and clinical course of
 1621 patients infected with SARS-CoV-2 in Singapore. *J. Am. Med. Assoc.* 323, 1488–1494.
 1622 <https://doi.org/10.1001/jama.2020.3204>
 1623 Yu, I.T.S., Qiu, H., Tse, L.A., Wong, T.W., 2014. Severe acute respiratory syndrome beyond amoy
 1624 gardens: Completing the incomplete legacy. *Clin. Infect. Dis.* 58, 683–686.
 1625 <https://doi.org/10.1093/cid/cit797>
 1626 Yuan, S., Liao, Z., Huang, H., Jiang, B., Zhang, X., Wang, Y., Zhao, M., 2020. Comparison of the
 1627 indicators of psychological stress in the population of Hubei Province and non-endemic
 1628 provinces in China during two weeks during the Coronavirus Disease 2019 (COVID-19)
 1629 outbreak in February 2020. *Med. Sci. Monit.* 26, e923767.
 1630 <https://doi.org/10.12659/MSM.923767>
 1631 Zang, R., Castro, M.F.G., McCune, B.T., Zeng, Q., Rothlauf, P.W., Sonnek, N.M., Liu, Z., Brulois,
 1632 K.F., Wang, X., Greenberg, H.B., Diamond, M.S., Ciorba, M.A., Whelan, S.P.J., Ding, S.,
 1633 2020. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal
 1634 enterocytes. *Sci. Immunol.* 5:eabc3582. <https://doi.org/10.1126/sciimmunol.abc3582>
 1635 Zhang, D., Ling, H., Huang, X., Li, J., Li, W., Yi, C., Zhang, T., Jiang, Y., He, Y., Deng, S., Zhang,
 1636 X., Liu, Y., Li, G., Qu, J., 2020e. Potential spreading risks and disinfection challenges of
 1637 medical wastewater by the presence of Severe Acute Respiratory Syndrome Coronavirus 2
 1638 (SARS-CoV-2) viral RNA in septic tanks of Fangcang Hospital. *Sci. Total Environ.* 741,
 1639 140445. <https://doi.org/10.1016/j.scitotenv.2020.140445>
 1640 Zhang, H., Kang, Z., Gong, H., Xu, D., Wang, J., Li, Z., Cui, X., Xiao, J., Meng, T., Zhou, W., Liu,
 1641 J., Xu, H., 2020c. Digestive system is a potential route of COVID-19: an analysis of single-cell
 1642 coexpression pattern of key proteins in viral entry process. *Gut* 69, 1010-1018.

1643 <http://dx.doi.org/10.1136/gutjnl-2020-320953>

1644 Zhang, T., Cui, X., Zhao, X., Wang, J., Zheng, J., Zheng, G., Guo, W., Cai, C., He, S., Xu, Y.,
1645 2020a. Detectable SARS-CoV-2 viral RNA in feces of three children during recovery period
1646 of COVID-19 pneumonia. *J. Med. Virol. In press*. <https://doi.org/10.1002/jmv.25795>

1647 Zhang, W., Du, R.H., Li, B., Zheng, X.S., Yang, X. Lou, Hu, B., Wang, Y.Y., Xiao, G.F., Yan, B.,
1648 Shi, Z.L., Zhou, P., 2020b. Molecular and serological investigation of 2019-nCoV infected
1649 patients: implication of multiple shedding routes. *Emerg. Microbes Infect.* 9, 386–389.
1650 <https://doi.org/10.1080/22221751.2020.1729071>

1651 Zhang, Y., Chen, C., Zhu, S., Shu, C., Wang, D., Song, J., 2020d. Isolation of 2019-nCoV from a
1652 stool specimen of a laboratory-confirmed case of the Coronavirus Disease 2019 (COVID-19).
1653 *China CDC Wkly.* 2, 123–124. <https://doi.org/10.46234/ccdcw2020.033>

1654 Zhou, J., Li, C., Liu, X., Chiu, M.C., Zhao, X., Wang, D., Wei, Y., Lee, A., Zhang, A.J., Chu, H.,
1655 Cai, J.P., Yip, C.C.Y., Chan, I.H.Y., Wong, K.K.Y., Tsang, O.T.Y., Chan, K.H., Chan, J.F.W.,
1656 To, K.K.W., Chen, H., Yuen, K.Y., 2020. Infection of bat and human intestinal organoids by
1657 SARS-CoV-2. *Nat. Med.* 26, 1077-1083. <https://doi.org/10.1038/s41591-020-0912-6>


1658 Zhou, J., Li, C., Zhao, G., Chu, H., Wang, D., Yan, H.H.N., Poon, V.K.M., Wen, L., Wong,
1659 B.H.Y., Zhao, X., Chiu, M.C., Yang, D., Wang, Y., Au-Yeung, R.K.H., Chan, I.H.Y., Sun, S.,
1660 Chan, J.F.W., To, K.K.W., Memish, Z.A., Corman, V.M., Drosten, C., Hung, I.F.N., Zhou, Y.,
1661 Leung, S.Y., Yuen, K.Y., 2017. Human intestinal tract serves as an alternative infection route
1662 for Middle East respiratory syndrome coronavirus. *Sci. Adv.* 3, eaao4966.
1663 <https://doi.org/10.1126/sciadv.aao49660>

1664 Zhu, X., Ge, Y., Wu, T., Zhao, K., Chen, Y., Wu, B., Zhu, F., Zhu, B., Cui, L., 2020. Co-infection
1665 with respiratory pathogens among COVID-2019 cases. *Virus Res.* 285, 198005.
1666 <https://doi.org/10.1016/j.virusres.2020.198005>

1667 Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J.,

1668 Guo, Q., Song, T., He, J., Yen, H.-L., Peiris, M., Wu, J., 2020. SARS-CoV-2 viral load in
1669 upper respiratory specimens of infected patients. *N. Engl. J. Med.* 382, 1177–1179.
1670 <https://doi.org/10.1056/NEJMc2001737>

SARS-CoV-2 Release Pathways




Sewage networks



Wastewater treatment



River systems



Coastal systems



SARS-CoV-2 Infection Pathways

Highlights

- SARS-CoV-2 RNA can be readily detected in feces and occasionally urine
- Severe GI dysfunction only occurs in a small number of cases ($11 \pm 2\%$)
- Likelihood of SARS-CoV-2 being transmitted via feces appears very low
- Likelihood of infection from sewage-contaminated water or food is extremely low




Figure 1. Summary of symptoms experienced in clinically reported SARS-CoV-2 infections. The data is the summary of 48 independent reports involving a total of 3706 patients. The yellow bars are those associated with gastrointestinal problems. In the box plots, the boundary of the box closest to zero indicates the 25th percentile, a black line within the box marks the median, and the boundary of the box farthest from zero indicates the 75th percentile. Whiskers above and below the box indicate the 10th and 90th percentiles. Points above and below the whiskers indicate outliers outside the 10th and 90th percentiles. The average size of the cohort studies was 79 ± 21 ($n = 48$).




Figure 2. Temporal dynamics of SARS-CoV-2 in the sputum, throat and stools. Data are from a cohort ($n = 32$) of COVID-19 patients in China. Adapted from Huang et al. (2020).




Figure 3. Prevalence of human pathogenic viruses in nasopharyngeal and stool samples from individuals ($n = 331$). The points represent individual viruses including Human Coronavirus (HCoV), Influenza A, Influenza B, Human Rhinovirus (HRV), Respiratory syncytial virus (RSV), Human Adenovirus (HAdV), Human Bocavirus (HBoV) and Human Parainfluenzavirus (HPIV). Data calculated from (Minodier et al., 2017).




Figure 4. Main routes by which SARS-CoV-2 leaves the body (left), and a summary of the mechanism of viral replication (right).




Figure 5. Summary of the main infection pathways by which SARS-CoV-2 can theoretically contaminate the environment and cause secondary infections. The numbers denote the major pathogen transport routes and exposure points: (1) contamination of toilets by infected individuals, aerosolization of feces/urine, faulty plumbing in buildings (2) pathogen transfer in the sewer network and potential exposure to sanitation workers in the sewer network, (3) discharge of untreated contaminated wastewater to rivers (sewer overflows), (4) release in bioaerosols from wastewater treatment plants and exposure of workers to potentially contaminated wastewater, (5) release of treated wastewater to rivers, (6) disposal of wastewater-derived biosolids to land, (7) transport in freshwater and exposure of individuals during recreational activities, (8) abstraction of river water for human consumption, (9) breaks in sewage pipes leading to groundwater contamination (10) hospital/medical centre release of wastewater, (11) contamination of groundwater from burial of infected bodies, (12) irrigation of crops with potentially contaminated water abstracted from rivers, (13) contamination of marine waters, dispersal in the coastal zone and potential contamination of fish/shellfish and people engaging in recreational activities.

Table 1. Comparison of the properties of SARS-CoV-2 with Norovirus, a virus with known fecal-oral transmission.

	SARS-CoV-2	Norovirus
Family	Coronaviridae	Caliciviridae
Type	+ssRNA	+ssRNA
Shape	Spherical	Icosahedral
Genome size (kbp)	29.9	7.5
Size (nm)	50-200	23-40
Coating	Enveloped	Non-enveloped
Human infections per year	>7 million (Nov. 2019-Jun. 2020)	685 million
Primary symptoms	Respiratory problems, fever, GI pain	Diarrhea, GI pain, vomiting
Prevalence of diarrhea (% of total cases)	11	88
Incubation period	5-7 d	1-3 d
Symptom duration	7-14 d	2-5 d
Death rate (% of total infections) ^a	1.40	0.003
Shedding rate in feces (gc/ml)	10 ² -10 ⁷	10 ⁸ -10 ¹⁰
Shedding duration after symptoms have subsided (d)	14-28	14
Infectious dose (PFU) ^b	Unknown (estimate 10 ² -10 ³)	10 ¹ -10 ²
Vaccine available	No	No
Cases directly linked to fecal-oral transmission	None	Frequent
Links to consuming contaminated water	None	Infrequent
Links to consuming contaminated food	None	Frequent
Individuals most at risk of complications	Elderly	Elderly
Environmental durability	Low	High
Sensitivity to low pH	High	Low
Sensitivity to alcohol	High	Low
Sensitivity to chlorine	High	Medium-high

^aDeaths after accounting for both confirmed cases and estimates of asymptomatic carriage.

^bInfection mediated via the gastrointestinal tract. Only an estimate is available for SARS-CoV-2.

^cValues from the main text and from published values (Li et al., 2021; Robilotti et al., 2015; Hall et al., 2013; Pfeiffer, 2010; Kampf et al., 2020; Siddharta et al., 2017).